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ABSTRACT
We develop m athem atical models relating m easured biological markers to  how animals 
process nutrients and toxins. Our models track molecules as they  are ingested, transform ed 
through m etabolic processes, and excreted, and relate m easurem ents of biological markers 
to  these processes. We focus on specific problems of practical interest. We begin by 
developing a model of acetam inophen m etabolism  and use our model to  estim ate outcome of 
acetam inophen overdose patients. A cetam inophen overdose increasingly occurs as a result 
of chronic use. We analyze the dynamics of chronic use and find threshold dynamics th a t 
result from the structure  of acetam inophen metabolism. We next study animal nitrogen 
metabolism. Nitrogen stable isotope ratios in consumer tissue are used by ecologists to 
estim ate diet and trophic dynamics, but feedbacks between diet and physiology complicate 
the relationship between diet and the nitrogen isotope ratio of consumer tissue. We develop 
a model of animal nitrogen m etabolism  to study the influence of diet on stable nitrogen 
isotope ratios of consumer tissue. Finally, hair is often measured to  understand how animals 
process nutrients and toxins because organic and inorganic substances are incorporated into 
hair, remaining inert for long periods of time. We develop a model based on the known 
physiology of hair growth to  describe the signal averaging caused by bundling m ultiple hairs 
for segmental analysis.
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Animals ideally process nutrients and toxins in a way th a t maximizes the opportunity  
for growth and reproduction while minimizing dam age, dynamically altering their response 
to  changing inputs and environm ental conditions. Complex cascades of regulation, fine- 
tuned through generations of selected refinement, allow for a dynamic, adaptive response 
to  ever-changing conditions. In animals, the liver plays a central role in this regulation. 
Hepatocytes are responsible for detoxification of the blood and processing nutrients, and as 
such play a m ajor role in the regulation and control required to  m aintain homeostasis.
Those interested in understanding how animals process nutrients and toxins m ust make 
observations and measurem ents. D ata  m ust be collected and interpreted, experiments 
refined, bu t it is often impossible or im practical to  m easure the process of interest directly. 
Instead, researchers rely on indirect measurem ents of biological markers. T he complexity 
of life, the regulation and control, often leads to  a complex, nonlinear relationship between 
m easurem ents and the process of interest.
We wish to  understand how animals process nutrients and toxins by be tte r interpreting 
measurem ents. We ideally connect measurem ents of biological markers to  the biological 
sta te  or process of interest w ith m athem atical models accounting for the regulation and 
control th a t is central to  physiology, lending new insight to  measurements. Questions arise 
from hum an disease, hum an and anim al nutrition, or ecology, bu t rely on a mechanistic 
understanding metabolism. The m athem atics is built upon conservation. We dynamically 
track nutrients and toxins as they are ingested, transform ed, and excreted, and link these 
processes to  m easurable biological markers. Using our m athem atical models, we further 
in terpret the m arker m easurem ents to  gain new insight.
W hile we are interested in how animals process nutrients and toxins in general, we focus 
on specific questions of practical interest. We begin in Ch. 2 by developing a model of 
acetam inophen toxicity. We wish to  understand how the liver processes acetam inophen and 
how the build up of toxic m etabolites causes liver damage. W hile safe in small doses, large
2doses of acetam inophen can lead to  acute liver failure and ultim ately death. We use our 
model to  interpret clinical d a ta  of markers of liver dam age to  predict if patients will live or 
die following an overdose. If a patient is predicted to  die, liver transplan tation  may be the 
only life saving treatm ent. In recent years, overdoses increasingly occur over a background 
of chronic use. In Ch. 3 we further analyze the dynamics of our model of acetam inophen 
toxicity, w ith the addition of chronic use. The structure of the dynamic response of the liver 
to  acetam inophen overdose leads to  a threshold system, such th a t damage occurs acutely, if 
a t all, even w ith chronic use. T he acute nature of liver injury creates characteristic injury 
curves and robust predictions of outcome using the model devloped in Ch. 2, even w ith a 
background of chronic use. The liver also plays a central role in protein metabolism. In 
Ch. 4 we develop a dynamic model of nitrogen metabolism. The model tracks the fate of 
nitrogen as it is ingested as protein, converted to  the toxic m etabolite ammonia, processed 
by the liver to  urea, and excreted. We use the model to  estim ate the role of dietary  protein 
intake on stable nitrogen isotope ratios of tissue. Finally, in Ch. 5 we develop a model of 
how chemical signals in hair are blurred in sample preparation. Drugs, chemicals, and toxins 
are incorporated into hair, which can be sampled segmentally to  provide a chronology of 
measurem ents. Variations of hair growth due to  physiology can blur the chemical signal of 
interest. We develop a model based on the physiology of hair growth th a t we use to  better 
in terpret measurem ents. The regulation and control th a t is central to  physiology leads to 
complex relationships between the signal of interest and m easured biological markers. The 
m athem atical models are built on known physiology, tracking molecules from ingestion to 
m easurem ent, and are used to  better in terpret the blurred signal of biological markers.
CHAPTER 2
MATHEMATICAL MODELING OF LIVER 
INJURY AND DYSFUNCTION AFTER  
ACETAMINOPHEN OVERDOSE: 
EARLY DISCRIMINATION  
BETW EEN SURVIVAL 
AND DEATH 1 
2.1 Introduction
A cetam inophen (A PA P: N-acetyl-para-am inophenol) is the leading cause of acute liver 
injury in the U nited States, accounting for some 56,000 emergency room visits, 26,000 
hospital admissions, and about 500 deaths annually [1]. A PA P toxicity is caused by the 
formation, w ithin hepatocytes, of N-acetyl-p-benzoquinoneimine (N A PQ I), a highly reactive 
benoquinonam ine [2, 3]. Intracellular N A PQ I initially binds to  glutathione (GSH), and is 
safely elim inated [4, 5]. Once GSH stores are depleted, residual free N A PQ I reacts with 
cellular components and causes injury to  A PAP-m etabolizing hepatocytes [6, 7]. Early 
adm inistration of the GSH precursor, N-acetylcysteine (N-Ac), ideally w ithin 12 hours of 
overdose, prevents life-threatening liver injury and ensures recovery [8]. L ater adminis­
tra tion  may limit the liver injury, bu t its utility  decreases with tim e [9]. In the presence 
of a sufficiently large overdose, the adm inistration of N-Ac beyond a certain tim e window 
becomes futile. In these cases, liver transplan tation  becomes the only life-saving measure.
A num ber of factors may determ ine w hether a dose of APAP is fatal. Among the most 
im portant are the size of the overdose and the tim e to  first adm inistration of N-Ac [8]. 
Unfortunately, these two values are frequently not available a t the tim e of admission to  the 
hospital: patients often arrive confused or comatose, the family is usually unaware of the
1 REPR IN TED  W ITH PERM ISSION FROM  HEPATOLOGY: Remien CH, Adler FR , W addoups L, Box 
TD, and Sussman NL. M athem atical modeling of liver injury and dysfunction after acetam inophen overdose: 
Early discrim ination between survival and death. Hepatology, 56(2):727-734, 2012.
4tim ing or the dose of drug taken, and concom itant use of other m edications or drugs often 
obscures the clinical picture.
We therefore sought a m ethod for rapidly determ ining the tim e of overdose, extent of 
injury, and likelihood of spontaneous survival using laboratory d a ta  available a t the tim e 
of admission. O ur m ethod is based on a m athem atical model th a t describes typical hepatic 
injury progression, dependent only on overdose am ount. F itting  patient laboratory values 
to  our m athem atical model allows for the estim ation of overdose am ount and tim ing, as 
well as a prediction of outcome. We tested the m athem atical model on 53 patients from 
the University of U tah.
2.2 Materials and methods
2.2.1 M odel background
Our m athem atical model, the Model of Acetam inophen-induced Liver Damage (MALD), 
is based on a reproducible pa tte rn  of APAP-induced liver injury. The enzymes aspartate  
am inotransferase (AST) and alanine am inotransferase (ALT) are released by injured hep- 
atocytes [10, 11]. These enzymes peak at about 36 hours from initial injury and have 
distinct injury and clearance curves. AST concentration in blood is initially approxim ately 
double th a t of ALT, w ith a clearance rate  of about 50 % every 24 hours. ALT peaks at 
about the same tim e as AST, but w ith a slower elimination rate  of about 33 % every 24 
hours [12]. These measures of dam age are complemented by a m easure of liver function, 
prothrom bin tim e/ international normalized ratio  (INR). Decreased production of essential 
clotting factors manifests as reduced clotting and increased INR, again w ith characteristic 
rates of increase and decay [13]. The values of AST, ALT, and INR at the tim e of admission 
thus encode the course of disease progression over tim e and can be used, w ith a suitable 
m athem atical model, to  estim ate initial dose and tim e of overdose.
2.2.2 M odel description
We developed a system of nonlinear ordinary differential equations to  describe the 
tem poral dynamics of APAP-induced acute liver failure (ALF) based on known mechanisms 
of APAP metabolism. The equations describe NAPQI production from APAP metabolism, 
g lutathione conjugation, hepatocyte death  by NAPQI, release and clearance of AST and 
ALT in the blood, hepatocyte regeneration, and clotting factor production (Fig. 2.1).
The dynamics of to ta l serum APAP (^ ) , intracellular NA PQ I concentration (N ), in tra­
cellular GSH concentration (G ), num ber of functional hepatocytes (H ), num ber of damaged
5hepatocyte
regeneration








F ig u re  2.1. A schematic diagram  representing the dynamics of the m athem atical model. 
A fraction of APAP is oxidized to  NAPQI, bound to  GSH, and safely eliminated. As GSH 
stores are depleted, NAPQI damages hepatocytes, releasing AST and ALT into the blood. 
Meanwhile, functional hepatocytes regenerate and produce essential clotting factors. Red 
represents the intracellular variables, yellow represents healthy and damaged hepatocytes, 
and blue represents markers of liver damage.
6hepatocytes (Z ), serum AST concentration (S ), serum ALT concentration (L), and serum 
clotting factor concentration ( F ) are governed by the following system of ordinary differen­
tial equations:
APAP d A  =  - - 0 - A H  -
dt Hmax
NAPQI d N  =  H^ A  -  y N G
dt H max
dG
GSH —  =  k -  y N G  -  5g G
dt
dH  /  H  +  Z  \
Functional Hepatocytes =  r H  1 ---- —----- ) -  n N H
dt H max
dZ
Damaged Hepatocytes —  =  n N H  -  5z Z
dt
AST ddt =  Z  -  ^ ( S  -  Smin)
dt uH max
ALT ddL  =  Z  -  5l (L -  Lmin)
dt u n  max
d F  /  H  \
C lotting Factor —  =  ftpy jh-------- F j -
dt H max
H
APAP is cleared by conjugation at a rate  a —-----, and a small am ount is cleared
H max
unconjugated at rate  5a . A fraction p  of the APAP is converted to  NA PQ I and is cleared 
at a rate  7 G. GSH has a constant production k and decays at a ra te  5g . Hepatocytes grow 
logistically w ith ra te  r sa turating  at H max and become damaged at a rate  n N  releasing AST 
and ALT into the blood at rates 5z @s /(UHmax) and 5z PL/ ( 0Hmax), respectively. Clotting 
factors are produced by hepatocytes and decay at a rate  . INR ( I ) is related to  the 
concentration of clotting factors by the algebraic equation I  =  4.
The variables and param eters can be divided into those describing hepatocyte, APAP, 
glutathione, INR, and A ST/A LT dynamics. Functional hepatocytes (H ) become damaged 
hepatocytes (Z ) and regenerate w ith the following param eters:
•  The num ber of hepatocytes in a healthy liver is H max =  1.6 * 1011 cells [12, 14].
•  Damaged hepatocytes lyse with rate  5z  =  5 /day.
•  Functional hepatocytes regenerate w ith rate  r =  1 /day [15].
•  Functional hepatocytes become damaged with rate  n =  5.12 * 1013 cell/m ol/day.
•  The fraction of liver required for survival is ^  =  0.3 [16].
Serum APAP (A) is a surrogate for liver APAP, which is converted to  NA PQ I (N ) with 
the following param eters:
•  APAP is cleared by hepatocytes w ith rate  a  =  6 .3 /day [17].
•  APAP is cleared unconjugated w ith rate  5 a =  0.33/day [2, 3].
•  The fraction of APAP th a t is oxidized to  NAPQI is p =  0.5 [2, 3].
•  The conversion factor from grams of APAP to  mol of NA PQ I is q =  0.0067 m ol/g.
GSH (G) is associated w ith the following param eters:
•  GSH binds to  NAPQI with rate  y =  1.6 * 1018 cell/m ol/day  [18].
•  GSH decays w ith rate  =  2 /day  [19, 20, 21]
•  GSH is produced with ra te  k =  1.375 * 10-14 m ol/cell/day.
INR ( I ) is related to  the clotting factor concentration as a fraction of normal ( F ) and 
is associated w ith the following param eters:
•  Clotting factor VII is cleared with rate  ftp =  5 /day  [22].
•  The minimum clotting factor concentration is Fmin =  0.75.
Serum AST concentration (S) and serum ALT concentration (L) increase and decay 
w ith the following param eters:
•  AST is cleared with rate  5s  =  0.92/day [12].
•  ALT is cleared with rate  5l  =  0.35/day [12].
•  The to ta l am ount of AST in a healthy liver is 200,000 IU.
•  The to ta l am ount of ALT in a healthy liver is 84,800 IU.
•  The am ount of blood in a hum an body is d =  5 L.
•  The minimum AST level is S min =  12 IU /L .
7
8•  The minimum ALT level is L min =  9 IU /L .
Six param eters were adjusted to  m atch properties of the data, independent of patient 
survival information. The am ounts of AST and ALT in the liver, @s  and , respectively, 
were scaled to  the maximum observed AST and ALT values, and the minimum AST and 
ALT levels, Smin and L min, respectively, were scaled to  the minimum observed AST and 
ALT values. The minimum clotting factor concentration Fmin was scaled to  the maximum 
observed INR value. The damaged hepatocyte lysis rate  5Z was adjusted to  the tim ing of 
peak AST and ALT values.
Two param eters were scaled to  the dose of APAP required for hepatotoxicity and death. 
The glutathione production rate, k, was scaled to  the dosage at which glutathione reserves 
are depleted. The minimum dosage predicted to  lead to  hepatotoxicity varies, but typically 
ranges from 7.5 to  10 g for an adult [8, 23]. We chose a slightly lower value of 6.0 g 
for the dosage at which glutathione reserves are depleted. The rate  at which hepatocytes 
become damaged by NAPQI, n, is a scaling factor th a t was chosen so th a t a 20 g overdose 
is equivalent to  70 % hepatic necrosis and predicted death.
2.2 .3  P atien ts
Between January  1, 2006, and December 31, 2009, all hospital discharges from the 
University of U tah were queried for the diagnosis of severe, acute APAP toxicity. Charts 
were excluded if they included acute hepatitis A or B, autoim m une hepatitis, W ilson 
Disease, or m ultisystem  failure. Laboratory d a ta  and admission and discharge notes were 
further reviewed to  identify cases in which acute liver disease was due to  APAP overdose 
only. C harts th a t had overdose w ith additional m edications were not included in this analy­
sis. Demographics, N-Ac adm inistration, and medical outcome information were collected. 
Laboratory results of AST, ALT, INR, bilirubin, and creatinine were also collected. Charts 
w ithout a t least one m easure of AST, ALT, and INR were excluded from the study. In 
to tal, 53 patients were included. The patient population was diverse, w ith varying alcohol 
use, body mass index, and ingestion type, including suicide a ttem pts, single accidental 
overdoses, and multiple day chronic overdoses.
2.2 .4  E th ics sta tem en t
Patien t consent was not obtained because d a ta  were retrospective, were based on stand­
ard care, and were analyzed anonymously. The protocol was approved by the Institu tional
9Review Board (IRB) of the University of U tah  in accordance w ith the D eclaration of 
Helsinki.
2.2.5 Serum  creatin ine
Serum creatinine was added as an additional criterion separate from the model because 
it is a m arker of kidney dam age and our dynamic model does not describe kidney damage. 
Because kidney function is ultim ately im portant in survival in APAP overdose, patients 
with serum creatinine greater than  3.4 m g/dL  were predicted to  die [24].
2.2 .6  F ittin g  th e  m odel to  ind ividual p atien ts
Upon admission, before adm inistration of N-Ac, a p a tien t’s AST, ALT, and INR values 
in the m athem atical model are a function of two param eters, APAP overdose amount, 
A 0, and tim e since overdose, t . These two param eters were estim ated using weighted 
least-squares and values of AST, ALT, and INR on admission. The weights were determ ined 
by posttreatm ent model fits.
2.2 .6 .1  P osttrea tm en t m odel fits
To estim ate uncertainty in m easurem ents of AST, ALT, and INR, we define a p osttrea t­
ment model as a special case of the pretreatm ent model. Treatm ent w ith N-Ac leads to 
a high concentration of intracellular GSH, preventing further damage to  hepatocytes (i.e., 
N  =  0). This reduces the AST subsystem  to
i z  =  a z  
~dt =  -A z z
i S  AZ Ps  ry W c  e \
z  aS (S Smin) ?i t  OH,max
the ALT subsystem to
i Z  A Z
m  =  -A z z
i L  AZ p L z  A (T T  ^
i t  =  OH z  °L(L  Lmin),i t  OHmax
and the INR subsystem  to
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d z  S Z 
d  =  —S z z  
dH  „ „  H  +  Z—  =  rH (1  -  — ----- )
dt Hmax
d F  _  o ( H  _ ) 
~dt =  ° F (H  F )dt Hmax
I /  1 +  Fmin \
' F  +  Fmin'
The posttreatm ent model subsystems were fit to  individual patients using least squares. 
In the AST subsystem, the modeled AST value is a function of two param eters, the modeled 
AST concentration at the tim e of admission, S0, and the num ber of damaged hepatocytes on 
admission, Z0. For each individual patient, the best fit solution is the one th a t minimizes, 
over all possible combinations of S 0 and Z 0, the sum of the squared residual
2
]T ( lo g (A S T i)  -  log(Si(So,Zo))) ,
where A S T  is the p a tien t’s m easured AST value i days after the first m easurem ent, and 
Si (S0, Z0) is the modeled AST value i days after the first m easurem ent w ith initial conditions 
S0 and Z0. All logarithm s indicate the natural log. The residual for each measurement 
is defined as log(ASTi) — log ^Si (S 0 ,Z 0 )j where S0 and Z0 are the AST and damaged 
hepatocyte initial conditions th a t minimize the least squares problem, respectively. The 
standard  deviation of all of the residuals from all m easurem ents of AST from all patients 
is =  0.60.
Using the same approach described above, bu t replacing ASTi , Si , and S0 by ALTi , Li , 
and L 0, respectively, the standard  deviation of all of the residuals from all measurem ents 
of ALT from all patients is w l =  0.43.
For INR, the modeled value / i depends on three param eters, modeled clotting factor 
concentration at the tim e of admission, F 0, modeled num ber of damaged hepatocytes at 
admission, Z0, and modeled num ber of functional hepatocytes a t admission, H 0. Again 
minimizing the least squares difference between measured /N R i and modeled / i (F0, Z0, H 0), 
the standard  deviation of the residuals from all m easurem ents of all patients is w/  =  0.26.
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2.2 .6 .2  P retrea tm en t m odel fits
For each patient, the estim ated A0 and t  are those th a t minimize
log(AST) -  log(S(A o, t )) " log(A L T ) -  log(L (A o,t)) \ 2)
lo g (IN R )  -  log(I (A o ,t)) \  2)
where A S T , A L T , and IN R  are a p a tien t’s m easured AST, ALT, and INR on admission, 
and S , L, and I  are modeled AST, ALT, and INR for overdose am ount A0 a t tim e t  since 
overdose.
The line separating predicted recovery and predicted death  in Fig. 2.2 was determ ined 
by numerically solving the full pretreatm ent model for a range of A0, m arking the tim e 
since overdose when H  equals 30 % of its initial value (i.e., 70 % hepatic necrosis occurs). 
The estim ated probability of death  for each patient is calculated as the fraction of R within
2 of R* for which A0 and t  lie in the region of predicted death.
The confidence regions of A0 and t  for individual patients in Figs. 2.3, 2.4, 2.5, and 2.6 
are defined as follows. We begin w ith the best least squares estim ate for A0 and t , where 
the residual R takes its minimum R*. We then  find regions A0 and t  for which R is w ithin 
0.5 of R*, R exceeds R* by 0.5 to  1, R exceeds R* by 1 to  1.5, and R exceeds R* by 1.5 to
2 .
To test the sensitivity of model predictions to  param eters, we fit patients to  the pre­
treatm ent model with each param eter perturbed  by 50 % and 150 % of its original value.
We tested the model on 53 patients from the University of U tah. The tim e since overdose 
and overdose am ount were estim ated for each patient using initial m easurem ents of AST, 
ALT, and INR on admission (Fig. 2.2). Based on the extent of estim ated liver injury, the 
model predicts death  for patients who took over 20 g of APAP w ithout N-Ac adm inistration 
within the first 24 hours.
Excluding patients who were transplanted, death  versus recovery was predicted w ith 75 
% sensitivity and 95 % specificity (Tab. 2.1). W ith  the addition of initial serum creatinine 
exceeding 3.4 m g/dL , sensitivity increased to  100 %. For this dataset the subset of the 
Kings College C riteria (KCC) to  which we had access (INR >  6.5 and creatinine >  3.4 
m g/dL) had 13 % sensitivity and 100 % specificity. Only one patient had both  INR >  6.5 
and creatinine >  3.4 on admission. Thinking of the KCC as either INR >  6.5 or creatinine >
2.3 Results
T a b le  2.1. Sensitivity, specificity, PPV , and NPV for a subset of K ing’s College Criteria (INR >  6.5 and creatinine >  3.4), either 
INR >  6.5 or creatinine >  3.4 m g/dL , and the current study both  w ith and w ithout creatinine as an independent marker. Absolute 
numbers and 95% Clopper-Pearson confidence interval are given in parentheses.
Model Specificity Sensitivity P P V NPV
INR >  6.5 and creatinine >  3.4 
m g/dL
INR >  6.5 or creatinine >  3.4 
m g/dL
MALD (No Creatinine)
MALD (W ith Creatinine)
1 (43/43, 0.92-1)
0.95 (41/43, 0.84-0.99)

























predicted overdose amount (g)
F ig u re  2.2. MALD derived estim ates of tim e since overdose and overdose am ount for 53 
patients w ith known APAP overdose. Red squares indicate eventual death, green circles 
recovery, and orange triangles transplant. Small white dots indicate INR >  6.5 and small 
black dots indicate serum creatinine >  3.4 m g/dL  on admission. The gray line indicates 
overdose am ounts and tim es since overdose for which 70 % hepatic necrosis is predicted. 
P atien ts to  the right and above the gray line are predicted to  die.
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estimated overdose amount (g)
F ig u re  2.3. Markers of liver damage (small black open circles) and model predictions (red 
dashed line) based on least squares fits of initial AST, ALT, and INR (large black filled 
circle) to  modeled AST, ALT, and INR (large red filled circle). Time t =  0 indicates the 
tim e of admission to  hospital. The estim ated overdose am ount and tim e since overdose for 
each patient is given by the orange dot in the lower right panel.
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F ig u re  2.4. Markers of liver damage (small black open circles) and model predictions (red 
dashed line) based on least squares fits of initial AST, ALT, and INR (large black filled 
circle) to  modeled AST, ALT, and INR (large red filled circle). Time t =  0 indicates the 
tim e of admission to  hospital. The estim ated overdose am ount and tim e since overdose for 
each patient is given by the orange dot in the lower right panel.
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F ig u re  2.5. Markers of liver damage (small black open circles) and model predictions (red 
dashed line) based on least squares fits of initial AST, ALT, and INR (large black filled 
circle) to  modeled AST, ALT, and INR (large red filled circle). Time t =  0 indicates the 
tim e of admission to  hospital. The estim ated overdose am ount and tim e since overdose for 
each patient is given by the orange dot in the lower right panel.
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estimated overdose amount (g)
F ig u re  2.6. Markers of liver damage (small black open circles) and model predictions (red 
dashed line) based on least squares fits of initial AST, ALT, and INR (large black filled 
circle) to  modeled AST, ALT, and INR (large red filled circle). Time t  =  0 indicates the 
tim e of admission to  hospital. The estim ated overdose am ount and tim e since overdose for 
each patient is given by the orange dot in the lower right panel.
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3.4 m g/dL  increased sensitivity to  88 %. We did not have access to  patient encephalopathy 
or arterial pH.
Using only d a ta  available on admission, the model results fit the posttreatm ent time- 
series of the markers of liver damage for the m ajority of individual patients (Tab. 2.2). The 
results from four representative patients are shown in (Figs. 2.3, 2.4, 2.5, 2.6). Patien ts 5 and 
8 were predicted to  have had overdoses th a t were very close to  the lethal threshold, whereas 
patient 49 was predicted to  have exceeded the lethal threshold. Patien t 16 was predicted to 
have had a smaller overdose. The confidence region for some patients who recovered (e.g., 
patient 16) includes regions with high overdose am ount and very early N-Ac adm inistration, 
as well as regions w ith low overdose am ount and late N-Ac adm inistration. In both  cases 
AST, ALT, and INR are low.
Model predictions of outcome were robust to  50 % increase or decrease in param eter 
values (Tab. 2.3). The most sensitive model param eters were the fraction of liver required for 
survival, ^ , the am ount of AST in the liver, pS , and the decay rate of AST, AS. Increasing ^  
to  0.45 caused more patients who eventually recovered to  be predicted to  die, and resulted 
in 100 % sensitivity and 77 % specificity, whereas decreasing ^  to  0.15 resulted in 88 % 
sensitivity and 93 % specificity. Increasing p S by 50 % resulted in 100 % sensitivity and 
79 % specificity, whereas decreasing pS by 50 % resulted in 88 % sensitivity and 88 % 
specificity. Increasing AS by 50 % resulted in 100% sensitivity and 91 % specificity, whereas 
decreasing AS by 50 % resulted in 88 % sensitivity and 74 % specificity.
Some param eters such as p, the fraction of APAP oxidized to  NAPQI, have a large effect 
on predicted dose of APAP, but no effect on predicted outcome. If p is 0.025, an overdose 
am ount of 40 g is required for 70 % hepatic necrosis and predicted death, whereas if p  is 
0.075, an overdose am ount of 13.3 g is required for 70 % hepatic necrosis and predicted 
death. Estim ates of overdose am ount scale with lethal dose so th a t estim ates of outcome 
rem ain the same despite large changes in estim ated overdose am ount.
2.4 Discussion
APAP, alone or in combination, accounts for about 50 % of cases of ALF in the USA 
[25]. Survival largely depends on two param eters: the size of the initial dose and tim e 
elapsed prior to  the adm inistration of N-Ac. Very early adm inistration (up to  12 hours 
after overdose) of N-Ac results in almost 100 % survival [8].
T a b le  2.2. Observed AST, ALT, INR, creatinine, and result, and predicted overdose am ount A0, tim e since overdose t , predicted 
result w ithout creatinine, residual, and estim ated probability of death. Patients w ith predicted results m arked with a star (*) were 
predicted to  die w ith the inclusion of creatinine.___________________________________________________________________
patient
num ber





1 18 27 1.2 0.8 recovery 6.1 3.9 recovery 0.5 0
3 138 128 1.2 0.5 recovery 6.6 1.9 recovery 0.46 0
4 6023 3352 11 1.5 transplan t 25.1 4.4 death 3.73 1
5 6432 6390 3 3 recovery 18.9 3.2 recovery 0.23 0.12
6 5267 12202 4.3 0.6 recovery 20.5 3.4 death 0.82 0.44
8 11842 6731 3.9 2.6 recovery 16.3 1.6 recovery 0.46 0.15
9 2381 4960 1.6 0.8 recovery 18.5 4.2 recovery 0.03 0.16
10 26 19 1.1 0.7 recovery 5.8 1.4 recovery 0.13 0
11 1546 3642 1.4 0.7 recovery 17.9 4.6 recovery 0.26 0.18
14 313 402 1.1 0.6 recovery 7.6 2.5 recovery 0.09 0
16 1427 1497 1.2 0.8 recovery 9.6 2.2 recovery 0.1 0
17 29 18 1.1 0.6 recovery 5.8 0.8 recovery 0.13 0
18 17 11 1.3 0.4 recovery 7.1 0.2 recovery 1.04 0
21 14230 6746 10.5 2.7 death 22.2 2.9 death 1.36 0.99
22 52 21 1 0.6 recovery 8.1 0.2 recovery 0.11 0
25 184 48 1 0.7 recovery 17.3 0.1 recovery 0.58 0
26 15953 5598 2 2.8 recovery 40 0.4 recovery 0.46 0
28 28 17 1.1 0.8 recovery 5.8 0.7 recovery 0.13 0
29 10394 8392 3.7 5 death 17.5 2.4 recovery* 0.02 0.14
31 24 16 1.1 0.6 recovery 5.7 1 recovery 0.14 0
33 774 443 1.7 0.7 recovery 7.3 0.8 recovery 3.44 0
36 509 7686 3.3 4 death 25.1 6 d ea th* 2.84 1
37 53 19 1.1 0.5 recovery 9.9 0.1 recovery 0.39 0
38 69 71 1 1 recovery 6.3 2.2 recovery 0 0
39 8122 8134 3.8 0.8 recovery 19 2.9 recovery 0.03 0.17
41 443 3368 1.9 0.8 recovery 24.7 6.6 death 0.01 1
19
T able 2.2 cont.
patient
num ber





43 23 22 1.2 0.7 recovery 5.9 2.3 recovery 0.5 0
44 35 19 1.2 0.7 recovery 6 0.4 recovery 0.5 0
47 23 21 1.2 0.6 recovery 5.9 2.1 recovery 0.5 0
49 7454 5507 17.8 1.4 death 25.7 3.9 death 1.19 1
51 37 27 1.4 0.9 recovery 5.9 1.4 recovery 1.69 0
53 626 563 1.6 0.7 recovery 7.7 1.7 recovery 2.75 0
54 24000 15000 3.1 0.9 recovery 17 1.2 recovery 2.84 0.14
55 289 1884 1.1 0.6 recovery 15.1 5.9 recovery 0.07 0.31
58 21 35 1.2 0.7 recovery 6.2 3.9 recovery 0.5 0
59 5238 3641 17.3 2.8 death 26.4 4.5 death 2.65 1
60 6298 2792 21.1 3.8 death 27.1 4.5 death* 5.3 1
61 230 921 1.7 6.7 transplan t 10.5 4.7 recovery* 4.03 0.29
62 744 903 1.5 0.9 recovery 8.6 2.3 recovery 1.89 0
63 8029 6989 2 1 recovery 14.6 2.2 recovery 0.1 0
65 147 117 1.3 0.6 recovery 6.5 1.6 recovery 0.97 0
67 21 9 1.2 1 recovery 13.9 0.1 recovery 0.86 0
68 1621 1404 1.8 5.5 recovery 8.9 1.3 recovery* 3.11 0
71 10810 9218 4.4 2.4 recovery 18.4 2.5 recovery 0 0.23
74 5562 4449 2.2 3.5 death 13.1 1.7 recovery* 0.76 0.05
75 14520 9159 2.3 1.3 recovery 14.4 1.6 recovery 0.85 0.02
77 1545 1228 6.3 1.2 death 26.7 6.3 death 8.26 1
78 7716 5588 2.3 0.7 recovery 13.9 1.8 recovery 0.15 0
79 37 13 1.2 0.8 recovery 15.9 0.1 recovery 0.92 0
81 31 25 1.1 0.7 recovery 5.9 1.7 recovery 0.13 0
82 115 163 1.5 3.1 recovery 6.9 2.7 recovery 2.41 0
83 78 52 1.5 0.7 recovery 6.1 1.2 recovery 2.43 0
84 17161 12147 4.2 3.5 recovery 17.5 1.5 recovery* 0.42 0.23 20
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T a b le  2.3. A sum m ary of how changes in param eter values affect predictions of outcome.
Modified Param e­
ter
New Value Specificity Sensitivity P P V NPV
Current Study 
(W ith Creatinine)
0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
V 0.45 0.77 (33/43) 1 (8/8) 0.44 (8/18) 1 (33/33)
V 0.15 0.93 (40/43) 0.88 (7/8) 0.7 (7/10) 0.98 (40/41)
H max 2.4 * 1011 0.93 (40/43) 1 (8/8) 0.73 (8/11) 1 (40/40)
H max 8 * 1010 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
pF 7.5 0.88 (38/43) 0.88 (7/8) 0.58 (7/12) 0.97 (38/39)
pF 2.5 0.88 (38/43) 1 (8/8) 0.62 (8/13) 1 (38/38)
n 480 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
n 160 0.93 (40/43) 1 (8/8) 0.73 (8/11) 1 (40/40)
Pl 127200 0.88 (38/43) 0.88 (7/8) 0.58 (7/12) 0.97 (38/39)
Pl 42400 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
Ps 3 * 105 0.79 (34/43) 1 (8/8) 0.47 (8/17) 1 (34/34)
Ps 1 * 105 0.88 (38/43) 0.88 (7/8) 0.58 (7/12) 0.97 (38/39)
q 0.01005 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
q 0.00335 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
Sl 0.525 0.88 (38/43) 1 (8/8) 0.62 (8/13) 1 (38/38)
Sl 0.175 0.93 (40/43) 0.88 (7/8) 0.7 (7/10) 0.98 (40/41)
Ss 1.38 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
Ss 0.46 0.74 (32/43) 0.88 (7/8) 0.39 (7/18) 0.97 (32/33)
r 1.5 0.84 (36/43) 1 (8/8) 0.53 (8/15) 1 (36/36)
r 0.5 0.93 (40/43) 1 (8/8) 0.73 (8/11) 1 (40/40)
K 0.0033 0.91 (39/43) 0.88 (7/8) 0.64 (7/ 1 1 ) 0.98 (39/40)
K 0.0011 0.93 (40/43) 0.88 (7/ 8) 0.7 (7/10) 0.98 (40/41)
Sg 3 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
Sg 1 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
Sz 7.5 0.93 (40/43) 1 (8/8) 0.73 (8/11) 1 (40/40)
Sz 2.5 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
Y 1.5 * 107 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
Y 5 * 106 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
P 0.075 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
P 0.025 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
Sa 0.495 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
Sa 0.165 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
a 9.45 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
a 3.15 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
F ■1 mm 0.85 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
F1 mm 0.65 0.93 (40/43) 1 (8/8) 0.73 (8/11) 1 (40/40)
e 2.5 0.86 (37/43) 0.88 (7/8) 0.54 (7/13) 0.97 (37/38)
e 7.5 0.91 (39/43) 1 (8/8) 0.67 (8/12) 1 (39/39)
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Some models of APAP toxicity rely on the tim e between ingestion and hospital admission 
to  determ ine the need for treatm ent [17] or as a m easure of exposure [26]. These are 
risky approaches because the tim ing of the overdose provided by the patient is frequently 
unobtainable or unreliable. Moreover, patients who arrive at the hospital 24 hours or more 
postingestion may have plasm a APAP levels below the detection limit.
The KCC [24] provides a well-validated m ethod for predicting death  w ithout transp lan­
ta tion  in APAP-induced ALF [27], although they have been criticized for low sensitivity 
[28] and low negative predictive value (NPV) [29]. KCC used an initial dataset of 310 
patients to  identify statistically  significant prognostic indicators to  distinguish survivors and 
nonsurvivors and used a validation set of 121 patients to  identify cutoff values associated 
w ith survival rates less th an  20 % for the statistically  significant prognostic indicators, with 
no physiologically defined model of mortality. Many modifications of the KCC have been 
suggested [30, 31, 32, 33, 34, 35], perhaps most im portantly  the addition of arterial lactate 
[36]. A rterial lactate has consistently been shown to  be associated w ith survival, although 
its prognostic value has been questioned [37].
In contrast to  other modifications of the KCC, MALD is novel because we build upon 
the KCC by utilizing an understanding of the dynamics of hepatocyte damage following 
APAP overdose in the form of a dynamic m athem atical model. H epatic necrosis is directly 
related to  the extent of covalent binding of NAPQI to  intracellular components [2, 4, 6, 7], 
which causes hepatocyte lysis and release of AST and ALT into the blood. This produces a 
characteristic tim e course of injury w ith an early rise and predictable decay of AST, ALT, 
and INR. We have developed a system of differential equations based on the principles of 
APAP-induced liver damage. All param eters in MALD were estim ated from the literature, 
except six th a t were adjusted to  m atch general properties of AST and ALT dynamics, and 
two th a t were scaled to  the dosages thought to  cause hepatotoxicity and death. Survival 
information from University of U tah patients was not used in model development or param ­
eterization. The equations describe how AST, ALT, and INR levels change over tim e as a 
function of overdose am ount. Because these curves over tim e are only a function of initial 
overdose am ount, AST, ALT, and INR levels in the model only depend on initial overdose 
am ount and tim e since overdose. Our m ethod works by fitting m easured AST, ALT, and 
INR values to  the curves described by our differential equations to  estim ate overdose tim ing 
and am ount (Fig. 2.7). An outcome of death  is predicted when the estim ate of overdose 
am ount is sufficiently high and the estim ate of tim ing predicts N-Ac to  be ineffectual, or
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F ig u re  2.7. A schematic description of how MALD can be used to  estim ate overdose 
am ount, tim ing, and outcome. P a tien ts’ AST, ALT, and INR are fit to  a family of curves 
described by MALD to  estim ate overdose am ount, timing, and outcome. If outcome is 
predicted to  be poor, liver transplan tation  may be necessary.
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when serum creatinine m easurem ents are sufficiently high. If the outcome is predicted to 
be poor, liver transplan tation  may be the only life-saving treatm ent.
Previous studies have not found absolute am inotransferase levels to  be significant pre­
dictors of outcome in cases of APAP-induced ALF [24]. This is not surprising because 
am inotransferase levels will be low, even with a high dose, both  early and late in the course of 
the injury based on known mechanisms of liver dam age following APAP overdose. Similarly, 
high am inotransferase levels may be m easured near peak liver damage, even in cases of 
nonlethal overdose. In conjunction w ith INR and a suitable m athem atical model describing 
these mechanisms, however, am inotransferase levels do contain sufficient information to 
estim ate the tim ing and am ount of overdose.
Our model cannot distinguish patients w ith high overdose am ounts and early adminis­
tra tion  of N-Ac from patients w ith low overdose am ounts and delayed treatm ent because in 
both  cases AST, ALT, and INR levels are low. However, this ambiguity affects only patients 
who are predicted to  recover.
Some patients w ith unique characteristics, such as those w ith significant muscle damage, 
may not fit the model. Muscle damage increases the level of AST, which may lead to 
poor estim ation of liver damage. Because ALT and INR values are not affected by muscle 
damage, this effect may be minimal. Further studies are w arranted to  determ ine whether 
more refinements are needed for special patient groups.
Our treatm ent of all patients as having the same param eter values is unrealistic. Well- 
known covariates of disease severity such as age [38], chronic alcohol use [39, 40], starvation 
or m alnutrition [41], and interactions w ith o ther drugs [42, 43, 44] may affect the param eter 
values of an individual. In some cases these differences will not affect the accuracy of 
predictions of outcome. Model predictions derive from the am ount of unconjugated NAPQI 
th a t results from a given dose, bu t th a t am ount may depend on patient characteristics. 
For example, alcoholics may make excessive NAPQI because of elevated p-450 levels, or 
individuals may have decreased levels of GSH because of starvation, com petition from other 
drugs, or genetic variation. These differences might make the model estim ates of initial dose 
seem overly high, bu t the outcome could still be accurately predicted because these patients 
have more unconjugated NA PQ I th an  is typical for the overdose amount.
Jam es et al. [45] show th a t APAP protein adduct levels may be used as specific biom ark­
ers of APAP toxicity. If m easurem ents were routinely available, adducts could easily be 
added to  our model, and might provide additional predictive value. However, the correlation
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of protein adducts with AST and their similar kinetics lead us to  predict this effect would 
be small, although their more direct relationship to  liver damage might reduce noise and 
make them  a superior predictor.
Gregory et al. [46] found th a t individuals with overdose am ounts greater th an  10 g did 
not have significantly different m ortality than  those reporting smaller overdoses in patients 
w ith eventual hepatic encephalopathy. The authors suggest th a t this may be due to  inac­
curate reporting of dosing inform ation by patients w ith eventual hepatic encephalopathy, 
or from a plateau effect in APAP overdose am ount, such th a t above a threshold the effect 
of APAP overdose ceases to  be additive. A plateau is built into our model, but at 20 g 
ra ther th an  10 g. In our model, w ithout treatm ent, any overdose above 20 g will result in 
severe hepatic injury, maximal AST, ALT, and INR levels, and poor outcome. Our patient 
set is quite different because Gregory et al. required eventual hepatic encephalopathy for 
inclusion, a param eter unknown on admission and associated with poor prognosis [47].
M ethods to  determ ine w hether to  use dangerous and costly interventions, such as tran s­
plantation, will ideally be based on clinical d a ta  th a t are readily available a t the tim e 
of admission. Using only initial m easurem ents of AST, ALT, and INR, we were able to 
predict the hepatic injury progression and extent of liver dam age following APAP overdose. 
Unlike statistical models to  predict outcome, which m ust build on survivorship data, our 
m echanistic approach is based on the independently testable assum ption th a t 70 % hepatic 
necrosis leads to  death. Our dynamic model yields a prediction of outcome by estim ating 
the tim e since overdose and overdose am ount from commonly obtained laboratory da ta  on 
admission. W ith  the inclusion of creatinine, we were able, in this retrospective analysis, to 
predict survival versus death  w ith 91 % specificity, 100 % sensitivity, 67 % PPV , and 100 % 
NPV. Our initial analysis suggests th a t MALD compares favorably to  statistical methods, 
and should be validated in m ulticenter retrospective and prospective evaluation.
CHAPTER 3
CHRONIC ACETAMINOPHEN USE AND  
ACUTE LIVER INJURY  
3.1 Introduction
Acetam inophen is the most commonly used over the counter drug in the U nited States 
with over 40 % of adults reporting consum ption in a given m onth and 23 % reporting 
weekly use [48]. It is found in a t least 600 over the counter products, in pain relievers, fever 
reducers, cold and alergy medicines, and sleep aids, in tablet, gel tab , caplet and liquid form. 
From 1993 to  2007 there were over 750,000 emergency departm ent visits in the U nited States 
a ttribu tab le  to  APAP overdose [49]. W hile acute liver injury due to  acetam inophen overdose 
was historically the result of a single overdose, often a suicide a ttem pt, increasingly overdoses 
occur unintentionally, w ith dosages in excess of drug m anufacturer recom mendations for a 
period of several days [50]. Unintentional overdoses are associated w ith poorer outcome, 
possibly because they are often recognized only after symptoms have developed [51].
The reason for the increase in accidental overdose is likely multifaceted, but may partially 
be explained by consumer confusion. Since acetam inophen is found in com bination with 
many other drugs, people may exceed the recommended dosage by accidentally “double 
dipping,” not realizing th a t acetam inophen is present in m ultiple drugs, and taking more 
th an  intended. Consumers do not always adhere to  package or label instructions, a problem 
th a t is even more prevalent in patients with lim ited health  literacy [52].
Hepatotoxicity is often associated w ith short-term  fasting, chronic alcohol use, or use of 
P450-inducing m edications [39, 40, 41]. Each of these risk factors increases hepatotoxicity 
for a given dose by altering NA PQ I an d /o r glutathione dynamics. Short-term  fasting lowers 
glutathione production rate, P450-inducing medications increase the am ount of NAPQI 
produced for a given dose, and chronic alcohol use may either increase the am ount of NAPQI 
produced or compete for GSH, lowering the am ount of GSH available to  metabolize NAPQI.
We further analyzed the m athem atical model developed in Ch. 2 to  understand the 
effect of chronic APAP use on liver injury. The m athem atical model developed in Ch. 2
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assumed a single overdose, with APAP input only as an intial condition. Predictions of 
outcome were based on estim ates of tim e since overdose and the size of the APAP initial 
condition. We extended this model to  accom odate chronic acetam inophen use and analyzed 
model dynamics. We found th a t there is a threshold in the model w ith respect to  APAP 
intake and hepatocyte damage. Low intake produces no hepatocyte dam age since NAPQI 
is rapidly bound to  GSH and safely eliminated, bu t if APAP intake produces a quantity  
of NAPQI large enough to  fully deplete GSH reserves, hepatocyte damage ensues acutely. 
We fit our m athem atical model describing single overdose m arker dynamics to  synthetic 
markers of liver damage from overdose scenarios involving chronic use. The fits produced 
estim ated tim e since overdose, overdose am ount, and predicted outcome, w ith predicted 
outcome based on the minimum value of hepatocytes prior to  admission. We found th a t 
outcome could be accurately predicted from our synthetic data, even when the overdose 
occured on a background of chronic use, or as a result of a change in APAP metabolism 
efficiency.
We developed a model of acetam inophen m etabolism  and associated liver damage in 
Ch. 2. The model described below is identical to  the model in Ch. 2, but w ith an APAP 
intake term  in the serum APAP equation, a , and a small leak term  in the NAPQI equation 
unrelated to  GSH metabolism, 5N N . The small leak in the NA PQ I equation was added for 
m athem atical convenience, so th a t N  is bounded as H  goes to  zero.
3.2 Methods
3.2.1 C hronic acetam inophen  m etab olism  
and marker dynam ics
APAP
NAPQI
GSH —  =  K -  yN G  -  5o G 
dt
Functional Hepatocytes
Damaged Hepatocytes —  =  n N H  — 5ZZ
28
AST ddt =  Z  -  i s ( S  -  Smin)dt uH max
ALT ^  =  - H k -  Z  -  5l (L  -  Lmin)
dt —H max
d F  /  H  \
C lotting Factor —  =  ,0f ( h -------- F j .
dt ' H max '
In principle the param eters may be tim e-dependent. We will first consider the time- 
invariant chronic use case, and later develop tim e-variant chronic use scenarios, w ith APAP 
input, a , an d /o r GSH production, k, changing w ith time.
3.2.2 T im e-invariant chronic use
3.2 .2 .1  S tead y  sta tes
Setting the tim e derivatives to  zero, we found the steady states of A, G, Z , S, L, and 
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S * =  i s  ( - H r Z ' + i s  S




The steady states of H  in term s of the steady states of N  are H * =  0 and 
- i zH mox(n N * -  r)
H * = -------—-------- --------- . The steady sta te  of N  corresponding to  H * =  0 is the positive
r ( i z  +  nN  *) 
root of the quadratic equation
(iwiAHmaxY)N2 +  (-q p a a Y  +  YK^AHmax +  iw 5AH m axio)N  -  q p a a iG =  0.
- i z H max(n N * -  r)
The steady states of N  corresponding to  H * =  -------—-------- —------  are the roots of the
r ( i z  +  n N  *)
cubic equation a N 3 +  bN 2 +  cN  +  d =  0, where
a =5n H maxaSznY -  iwHmaxiArnY
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b =qpaarnY -  YKHmaxSArn -  Sn H maxaSzrY  +  Sn H maxaSzV$o -  Sn H max^ArSzY
+  YKHmaxadzn -  Sn H m axSzr^G  
c = qpaar5zY  -  YKHmaxSArSz +  qpaarr/^G -  YKHmaxaSzr -  5n H maxaSzrSG 
-  Sn  Hmax Sa  rSz  Sg 
d =qpaarSz  SG.
3.2 .2 .2  S tab ility  o f stead y  sta tes
Because the markers are not coupled to  the intracellular or hepatocyte equations, we 
need only determ ine the stability of intracellular and hepatocyte subsystem  to determ ine 
the stability of the steady states of the full system. Linearizing our system of intracellular 
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We found the steady states numerically for a range of acetam inophen input a, using 
param eter values described in Ch. 2, and SN =  10- 4 . We determ ined the stability of these 
steady states by numerically solving for the eigenvalues of J , evaluated at the steady states. 
We found a bifurcation at approxim ately a  =  0.34, when the H * =  0 steady sta te  changes 
stability, and another a t approxim ately a  =  6.83, a t which point the stable fixed point 
associated w ith H * & 1 and the unstable fixed point collide and vanish (Fig. 3.1). For a 
between approxim ately 0.34 and 6.83, the unstable fixed point has four eigenvalues with 
negative real part and one eigenvalue with positive real part.
3 .2 .2 .3  A pp roxim ation  o f b ifurcation  poin ts
Exam ining the steady states in the limit as y  goes to  infinity gives an approxim ation 
to  the bifurcation points (Fig. 3.2). The steady sta te  of N  corresponding to  H * =  0 is the 
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F ig u re  3.1. Bifurcation diagram s for APAP, NAPQI, GSH, and Hepatocytes as a fraction 
of normal, as a function of the bifurcation param eter APAP input a.
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(Sn Sa H maxYf)N2 +  ( -  qpaa7  +  YKSA—max +  Sn SA—maxSG)N -  qpaaSG =  0.
Dividing by 7  and taking the limit as 7  goes to  infinity, the fixed points of the approxim ate 
system satisfy
N * (Sn SAHmaxN* -  qpaa  +  KSAHmax) =  0.
This equation has degenerate roots when - q p a a  +  KSAHmax =  0, which, solving for a, gives
an approxim ate value for the bifurcation point of a  =  K—max^A .
qpa
- S z —max(n N * -  r)
Similarly, the steady states of N  corresponding to  — * =  -------—-------- ——-----  are the
r(oZ +  n N  *)
roots of the cubic equation a N 3 +  b N 2 +  c N  +  d =  0, where 
a =Sn  —m axaSzn i -  Sn  —maxSArrn
b =qpaarnY -  YK—maxSArn -  Sn  —m a x a S z n  +  Sn  —maxaSznSG -  Sn  —maxSArSz7 
+  YK—maxaSzn -  Sn  —m axSzr^G  
c = qpaarSz7  -  YK—maxSArSz +  qpaarnSG -  YK—maxaSzr -  Sn  —maxaSzrSG
-  Sn  —maxSArSzSg 
d =qpaarSZ Sg .
Dividing by 7  and taking the limit as 7  goes to  infinity, the fixed points of the approxim ate 
system satisfy N ( a N 2 +  bN  +  c) =  0, where
a = SN —maxaSZ n SN —maxSArn
b = qpaarn -  K—maxSArn -  Sn  —maxaSzr -  Sn  —maxSArSz +  K—maxaSzn  
c = qpaarSz -  k—maxSArSz -  k—maxaSzr
This equation has degenerate roots when c =  0, which, solving for a , gives an approxim ate
value for the bifurcation point of a  =  k—max(^A +  a ) .
qpa
3.2 .3  A P A P -in d u ced  liver injury on background o f chronic use
We explored the effect of chronic use in combination with APAP overdose or change 
in m etabolic efficiency on APAP-induced liver injury. We considered five tim e-variant 
scenarios. Three scenarios involved constant chronic APAP use followed by a dose of APAP 
in the form of a pulse of size A over. The three scenarios we considered were constant chronic 
APAP use prior to  overdose followed by continued constant APAP use, continued constant
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o g/day
F ig u re  3.2. Bifurcation diagram  for H epatocytes as a fraction of H max as a function of a  
for various values of 7 . As 7  approaches infinity, the two bifurcation points near a  =  6.9 
converge.
use for 1.5 days followed by no further acetam inophen use, and no further acetam inophen 
use after overdose (Fig. 3.3). We will refer to  these scenarios as a  continued, a  continued 
for 1.5 days, and a  discontinued, respectively.
We also considered two tim e-variant scenarios w ith constant APAP input and lowered 
GSH production levels for 1.5 days. GSH production can decrease for a variety of reasons 
including m alnutrition or starvation, which may in itiate  liver damage, even w ith constant 
APAP input. The two scenarios we considered were constant chronic APAP input with 
GSH production decreased to  some fraction of normal for 1.5 days w ith continued constant 
APAP use, and constant APAP input with GSH production decreased to  some fraction of 














F ig u re  3.3. A schematic representation of three scenarios of chronic APAP use followed 
by an APAP overdose of size A over. The scenario a  continued has continued APAP input 
a t a constant rate  after A over, a  continued for 1.5 days has continued APAP at a constant 
rate  for 1.5 days after A over, and a  discontinued has no further APAP input after A over.
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levels (Fig. 3.4). We will refer to  these scenarios as k changing a  continued, and k changing 
a  continued for 1.5 days, respectively.
We numerically solved the differential equations for the five scenarios w ith tim e varying 
param eters for a range of A over, k as a fraction of normal, and a. For the three models 
with constant chronic APAP use followed by an overdose, initial conditions for N , G, H , Z ,
S, L, and F  were set to  the stable steady sta te  associated with H * & H max and the given 
chronic value of a. The initial condition for A  was set to  the sum of the A  steady state  
associated w ith H * & H max and A over. For the two models w ith constant chronic APAP 
use followed by lower GSH production, initial conditions for A, N , G, H , Z , S , L, and F  
were set to  the stable steady sta te  associated w ith H * & H max and the given chonic value 
of a .
For each combination of param eters, we tracked AST, ALT, and INR m arker levels and 
the minimum value of H  up to  a range of tim es since A over or change in k. Values of a  
ranged from 0 to  6 by 1 g/day, A over ranged from 0 to  30 by 2 g, and k as a fraction of 
normal ranged from 0 to  1 by 0.1. The differential equations were numerically solved for each 
combination of a  and Aover for each of the three models involving chronic acetam inophen 
use followed by overdose and for each combination of a  and k  as a fraction of normal for 
the two models involving reduced k for 1.5 days.
The case a  discontinued is approxim ately equivalent to  a single tim e overdose of a
larger am ount. Since 7  is large, the initial NAPQI produced by the overdose is rapidly
absorbed by GSH, until GSH reserves are depleted to  zero, and NA PQ I does not increase
until GSH reserves are fully depleted. Because 7  is large, the steady sta te  values of
all of the sta te  variables except A  and G  are approxim ately equal in the chronic use
case and the single tim e overdose case. W ith  a background of constant chronic use, the
am ount of APAP absorbed by GSH before GSH levels drop to  approxim ately zero from an
overdose is Hmax (  k — —— q a a  j . The level of A  for a chronic user before overdose 
qpdo V Hmax (a  +  5 a ) /
is — a ---------- . The equivalence in overdose am ount of the a  discontinued model and the
H  + 5 AH max
single tim e overdose model is thus
A =  A a  + H max (  k qpaa \  H„
A over,chronic — A over a  +  r I K
H max
+  5a  qp5c V Hmax (a  +  5a ) J qp5c
where A over,chronic is the overdose am ount in the a  discontinued case th a t is equivalent to 











F ig u re  3.4. A schematic representation of the two scenarios of chronic APAP use followed 
by decreased GSH production for 1.5 days. The scenario k changing, a  continued has 
continued APAP input a t a constant rate, while the scenario K changing, a  continued for 
1.5 days has no further APAP input after GSH production returns to  normal.
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3.2 .4  Single overdose fits to  chronic m odel marker dynam ics
To determ ine the ability of our single overdose model to  accurately predict outcome 
from liver injury m arker measurem ents arising from chronic use, we fit the AST, ALT, and 
INR values from the five scenarios w ith background chronic acetam inophen use to  the single 
overdose model described in Ch. 2 using weighted least squares a t times 1/2, 1, 2, 3, 4, 5, 6, 
7 days after the pulse of A over or change in k, using MALD as described in Ch. 2 (Fig. 3.5). 
Values of a  ranged from 1 to  6 by 1 g/day, A over ranged from 2 to  30 by 2 g, and k as a 
fraction of normal ranged from 0 to  0.9 by 0.1. The model fits estim ate an overdose amount 
and tim e since overdose for each patient. For each estim ated overdose am ount and time, 
we numerically solved the single tim e overdose model to  obtain an estim ated pre-admission 
minimum hepatocyte level and outcome.
3.3 Results
The tim e-invariant chronic use model has bifurcations with respect to  the APAP in­
put param eter a . There exists a bifurcation at approxim ately a i  =  KHmax A where
qpa
the fixed point associated w ith H * = 0  changes stability and another a t approxim ately
a 2 =  kHmax(iA +  a ) where the the stable fixed point associated w ith H * «  H max collides 
qpa
with an unstable fixed point and vanishes. In the limit as iA goes to  zero, all APAP 
is processed by hepatocytes and the fixed point associated w ith H * =  0 is stable for 
all positive a . The bifurcation at a 2 corresponds to  the ratio  of GSH production and 
NAPQI production. If GSH production is greater th an  NA PQ I production, the fixed 
point associated w ith H * «  H max is stable, whereas if NA PQ I production exceeds GSH 
production, the only stable fixed point is th a t associated w ith H * =  0.
The stability analysis indicates th a t for a  between a i  and a 2 there exists an unstable 
fixed point from which a separatrix  em anates. The fixed points associated w ith H * =  0 
and H * «  H max are stable for a  between a 1 and a 2, bu t a large enough pertu rbation  away 
from these fixed points can lead to  a transition  from one fixed point to  the other.
A perturbation  resulting in transition  from the fixed point associated w ith H * «  H max 
to  th a t associated w ith H * = 0  can occur for a variety of reasons. We developed five 
tim e-variant scenarios, two of which involve continued chronic use after a perturbation  in 
either APAP input, a , or GSH production, k. Figs. 3.6 and 3.7 show the APAP pulse 
and k deviation for 1.5 days required to  force a transition  from the fixed point associated 
with H * «  H max to  th a t associated w ith H * =  0. Also plotted is the APAP pulse and k
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------ a discontinued after 1.5 days, 
^const_5 i Aover_12i tiffle—3 days 
----- single time model 
Aest=22.9, timeest=2.45 days
time (days) time (days)
F ig u re  3.5. An example of m arker d a ta  from a chronic overdose scenario and the single 
tim e overdose fit. The single tim e overdose model MALD underestim ates the tim e since 
overdose by about 0.5 days, bu t estim ates the extent of hepatocyte damage well.
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deviation for 1.5 days required to  reach at least 90 %, 70 %, 50 %, and 30 % necrosis, w ithout 
treatm ent, for the three scenarios w ith APAP use eventually discontinued. Even when 
APAP use is discontinued im m ediately following overdose, the damage from an overdose 
over a background of chronic use is greater th an  from a typical single tim e overdose of a 
given dose because GSH levels are lowered from chronic use.
Figs. 3.8 and 3.9 show the am ount of necrosis w ithout treatm ent for the five tim e-variant 
scenarios as a function of APAP pulse, Aover (Fig. 3.8) and decreased GSH production for
1.5 days, k as a fraction of normal (Fig. 3.9). Chronic APAP use increased hepatic necrosis 
for a given dose. Continued APAP intake leads to  more hepatocyte damage th an  when 
APAP use is eventually discontinued. APAP intake after damage has already begun to 
occur results in greater damage th an  typical for a dose, as there are fewer hepatocytes to 
process the APAP.
We fit the m arker levels from the five chronic use tim e-variant scenarios a t times up 
to  a week after overdose or change in GSH production to  MALD, the single tim e overdose 
model described in Ch. 2, yielding an estim ated tim e since overdose, overdose am ount, and 
minimum hepatocyte level. We compared the estim ated tim e since overdose to  the actual 
tim e since APAP pulse or change in GSH production rate  (Tab. 3.1) and the the estim ated 
minimum hepatocyte level to  the actual minimum hepatocyte level actually produced by 
the five chronic use tim e-variant scenarios (Tab. 3.2 and Fig. 3.10).
3.4 Discussion
The antioxidant glutathione is extrem ely effective a t binding to  NAPQI, preventing the 
build up of NA PQ I th a t leads to  hepatocyte damage and ultimately, if enough NAPQI 
is produced, liver failure and death. If GSH production cannot keep pace with NAPQI 
production, intracellular NAPQI levels rapidly increase and acute liver damage ensues. The 
fast binding of GSH to  NAPQI leads to  a threshold system such th a t the rate  of NAPQI 
production m ust exceed the rate  of GSH production for NA PQ I to  build up enough to  cause 
liver damage.
The five tim e variant scenarios fit well to  the single overdose model. Time since overdose 
estim ates were best for the a  continued for 1.5 days and the a  discontinued scenarios. Time 
since overdose was estim ated least well for the k changing, a  continued scenario. In this 
scenario, it takes tim e for APAP to build up because of low GSH production, so there is a 
delay from the tim ing of decreased GSH production to  the onset of liver injury.
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T a b le  3.1. Simple linear regression of estim ated tim e since overdose to  actual tim e since 
APAP pulse or change in GSH production ra te  in the tim e-variant scenarios. Significant 
differences indicate intercept different from 0 and slope different from 1 . ***p < 0.001; 
**p < 0.01; *p < 0.050.1; •p < 0.1_______________________________________________
scenario intercept ±  s.e. slope ±  s.e. R 2
a  continued
a  continued for 1.5 days 
a  discontinued 
k changing, a  continued 
k changing, a  discontinued
0.227 ±  0.053*** 0.793 ±  0.013*** 0.845 
0.060 ±  0.019** 0.930 ±  0.005*** 0.983 
0.144 ±  0.020*** 0.974 ±  0.005*** 0.984 
1.083 ±  0.071*** 0.337 ±  0.017*** 0.453 
0.510 ±  0.058*** 0.789 ±  0.014*** 0.870
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T a b le  3.2. Simple linear regression of estim ated minimum value of hepatocytes for the 
single tim e point overdose fit to  the actual minimum hepatocyte level for the tim e-variant 
scenarios. Significant differences indicate intercept different from 0 and slope different from 
1. ***p < 0.001; **p < 0.01; *p < 0.050.1; • p < 0.1_______________________________
scenario intercept ±  s.e. slope ±  s.e. R 2
a  continued
a  continued for 1.5 days 
a  discontinued 
k changing, a  continued 
k changing, a  discontinued
0.003 ±  0.001** 0.992 ±  0.002*** 0.997 
0.000 ±  0.001 0.995 ±  0.002** 0.997 
0.002 ±  0.001. 1.002 ±  0.001 0.999 
0.002 ±  0.004 0.994 ±  0.004 0.993 
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F ig u re  3.6. The overdose am ount, A ouer, required for minimum hepatocyte level of 0.9, 
0.7, 0.5, and 0.3 for a given chronic APAP level a  for three scenarios. The separatrix  
boundary describes the A over required to  transition  from the steady sta te  associated with 
H * «  H max to  the steady sta te  associated with H * = 0  for the a  continued scenario.
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....... separatrix boundary
-----  k changing, o continued
----- k changing,
o continued for 1.5 days
H min -  0 9 H min -  0 7
a g/day a g/day
H min -  0 5 H min -
a g/day o g/day
Figure 3.7. The reduction of GSH production, k as a fraction of normal, required for 
minimum hepatocyte level of 0.9, 0.7, 0.5, and 0.3 for a chronic APAP level a for two 
k changing scenarios. The separatrix boundary describes the k as a fraction of normal 
required to transition from the steady state associated with H * «  Hmax to the steady state 
associated with H * =  0 for the k changing, a continued scenario.
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Figure 3.8. The extent of liver damage associated with a pulse overdose of amount Aover 
and a given level of chronic constant APAP input a for the three scenarios involving chronic 
input followed by a pulse overdose.
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Figure 3.9. The extent of liver damage associated with a given reduction of GSH 
production, K as a fraction of normal, and level of chronic constant APAP input, a , for 















a continued for 1.5 days 
a discontinued 
k changing, a continued 
k changing, a continued for 1.5 days
0.0 0.2 0.4 0.6 0.8 1.0
estimated Hmin
Figure 3.10. Estimated liver damage plotted against actual liver damage for 3120 
combinations of time, a, Aover, and k as a fraction of normal for the five time-varying 
chronic scenarios.
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The extent of hepatocyte necrosis was well estimated for all scenarios, even when time 
since overdose was poorly estimated (R 2 >  0.97 for all scenarios, Fig. 3.10, Tab. 3.2). 
Estimated intercepts were all very close to zero and slopes very close to one, indicating 
good fit between estimated liver damage and actual liver damage.
The threshold nature of the system leads to rapid liver injury when NAPQI production 
exceeds the threshold of GSH production. Either the liver is being injured rapidly, or it is 
not being injured since it is unlikely for APAP levels to be maintained at a level such that 
hepatocyte regeneration balances NAPQI production. Thus, APAP-induced liver injury is 
manifested as acute injury, even when APAP is used chronically. Since APAP-induced liver 
injury tends to be acute, hepatocyte injury dynamics are similar, even with chronic use.
Similar hepatocyte injury curves create similar marker dynamics. The characteristic 
time course of liver injury leads to good fits of markers from the five scenarios of chronic 
APAP use to the single overdose model MALD. Time since overdose is perhaps better 
thought of as time since initiation of liver injury since in some scenarios there is no single 
time of overdose. Surprisingly, even when time since onset of injury was poorly estimated, 
the extent of liver injury was well estimated. Because the extent of liver injury is what is 
used to predict outcome, predictions of outcome were robust, even when estimates of time 
since overdose and overdose amount were poor.
We considered five scenarios, though of course many others are possible. Some scenarios 
such as changing the fraction of APAP metabolized to NAPQI merely change the effective 
dosage, while others such as competition from other drugs may change model dynamics. 
The threshold nature of the system combined with the improbability of balance of NAPQI 
production with hepatocyte regeneration, however, leads us to predict that APAP-induced 
liver injury is generally acute, and thus predictions of the extent of liver injury are robust. 
In our model, we assume a constant intracellular GSH production rate. If GSH production 
is regulated in such a way so as to provide compensation for the lowered GSH levels due to 
chronic use, model dynamics may be altered and the impact of chronic use lessened.
Risk factors for APAP-induced liver injury can be easily understood in the context 
of our model. Short-term fasting, chronic alcohol use, and chronic use of P450-inducing 
medications all affect the model in different ways, but each increases the likelihood of 
hepatotoxicity for a given dose. Fasting can decrease GSH production, chronic alcohol use 
may decrease GSH production or increase the fraction of APAP metabolized to NAPQI, and 
P450-inducing medications increase the fraction of APAP metabolized to NAPQI. These
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factors modify the threshold, changing the APAP dosage required for NAPQI production 
to exceed GSH production.
The dynamics of our APAP overdose model exhibit threshold behavior, giving insight 
into why chronic APAP use leads to acute, rather than chronic, liver damage. The dynamics 
suggest that marker fits to MALD, which are based on a single time point overdose, 
can accurately estimate the degree of hepatotoxicity, even when the overdose occurs on 
a background of chronic use.
CHAPTER 4
HOW ANIMAL NITROGEN METABOLISM 
SHAPES ISOTOPIC SIGNATURES 
OF TROPHIC DYNAMICS 
4.1 Introduction
Community ecology relies on a thorough understanding of species interactions. Predator- 
prey relationships determine energy and nutrient flows, food web structure and dynamics, 
and mechanism of control of species abundance (e.g., top-down vs. bottom-up). An accu­
rate knowledge of these relationships is needed to predict how these factors change with 
disturbance and management. In practice, predator-prey relationships are complex, difficult 
to quantify, and often vary with time, changing with season or year. Direct observation 
is often impractical or impossible, making indirect methods to estimate and quantify an 
animal’s diet necessary. Stable isotopes are perhaps the most powerful indirect method 
available. Carbon, nitrogen, and sulfur stable isotopes in nutrients are incorporated into 
tissues, recording and integrating the isotopic signal of dietary sources [53, 54].
While the stable isotope ratios of diet are the major determinant of the stable isotope 
ratios of consumer tissue, isotopes do not act as pure tracers. Physiological and metabolic 
processes lead to the partial separation of light isotopes (e.g., 12C, 14N, etc.) from heavy 
isotopes (e.g., 13C, 15N, etc.) (Tab. 4.1). The difference between the stable isotope 
ratio of consumer tissue and diet is termed consumer tissue-diet discrimination. Nitrogen 
consumer tissue-diet discrimination tends to be positive [55], and the bioaccumulation of
15N can be used to estimate trophic position [56, 57]. The level of nitrogen consumer 
tissue-diet discrimination is highly variable with interesting feedbacks with diet quality 
[58, 59] and quantity [60, 61] that depend on physiology and metabolism. It has been 
suggested that as protein intake increases or protein quality decreases, nitrogen consumer 
tissue-diet discrimination increases. Other important physiological factors that can influence 
the nitrogen stable isotope ratio of tissue include nitrogen recycling in the gut [62, 63], 
tissue turnover [54], and metabolic routing [54, 64], the preferential allocation of certain
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Table 4.1. The difference between the nitrogen stable isotope ratios of consumer tissue and 
diet, termed nitrogen consumer tissue-diet discrimination, is highly variable and influenced 
by many related, potentially interacting factors that affect an organism’s metabolism and 
nitrogen budget.______________________________________________________________
Factor Reference
dietary protein quality [58, 59]
dietary protein quantity [60, 61]
total energy intake [65, 66, 67]
tissue turnover rate [68]
consumer class and species [55]
form of nitrogen excretion [55]
tissue and organ type [55]
amino acid type [69]
starvation and nutritional stress [65, 66, 67]
metabolic rate [70]
metabolic routing [64, 54]
gut nitrogen recycling [71]
pregnancy [72]
growth [73]
macronutrients to specific tissues. Because consumer tissue-diet nitrogen discrimination 
depends on physiology and metabolism, tissue nitrogen stable isotope ratio measurements 
can be used as a proxy for an animal’s metabolic and nutritional state if the physiological 
underpinnings are well understood.
Consumer tissue-diet nitrogen discrimination also varies with amino acid: certain amino 
acids have high amino acid-diet nitrogen discrimination, while other amino acids have 
isotope ratios more similar to diet [69]. This likely depends on the details of how nitrogen is 
exchanged between amino acids in synthesis and catabolism [61]. Amine groups containing 
14N are favored in biochemical reactions that affect nitrogen in amino acids (e.g., transam­
ination and deamination), which may result in preferential excretion of isotopically light 
nitrogen [74]. Though transamination may be important, isotopic fractionation associated 
with urea formation is thought to be largely responsible for nitrogen isotope tissue-diet 
discrimination [75].
We have developed a mathematical model that describes the basic nitrogen dynamics of 
an animal. Our model tracks nitrogen atoms in ingested molecules as they are transformed, 
incorporated into tissues, and excreted, and it predicts that a minimum nitrogen intake 
is required to maintain body protein reserves. We extended our model to track nitrogen
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stable isotope and calculated the nitrogen isotope tissue-diet discrimination for a range of 
nitrogen intake values, as well as the turnover of nitrogen isotopes in various pools after a 
diet switch.
4.2 Methods
4.2.1 Nitrogen cycling in an animal
The major source of nitrogen in animal tissues is dietary protein. Proteins in diet enter 
the gut, where they mix with proteins of endogenous origin, mostly shed cells of the mucosal 
lining, and are broken into constituent small peptides and amino acids. Amino acids in the 
gut are absorbed via sodium-dependent amino acid transporters into the portal vein where 
they are processed by the liver and enter the free amino acid pool in plasma [76]. Free amino 
acids in the blood feed body tissues, which are constantly turning over, and represent the 
largest store of nitrogen in an animal.
The size of the free amino acid pool in plasma is tightly regulated, as is the size of the 
protein pool, provided protein intake level exceeds a minimum threshold. Excess plasma 
nitrogen is processed by the liver and converted to urea, under a net reaction requiring 
equimolar amounts of glutamate, derived from plasma amino acids, and ammonia, which 
can be derived from glutamate [75]. Urea is concentrated in the kidneys and excreted, 
though about 30 % is transported to the gut where bacteria can hydrolize it to ammonia, 
a process known as urea nitrogen salvage. Gut bacteria also catabolize amino acids to 
ammonia, as well as synthesize amino acids from ammonia that may become usable to the 
animal [75]. Nitrogen is also lost in feces as proteins, amino acids, ammonia, and urea, as 
shed proteins such as skin and hair, and as ammonia and amino acids in urine.
4.2.2 Model description
We developed a system of nonlinear differential equations to describe the major compo­
nents of nitrogen cycling in an animal (Fig. 4.1).
dG p
Gut protein —-— =  a — YGGP +  v—PM P — 5GGP 
dt
dG aGut amino acid —-— =  Yg Gp  — $ g lGa — kgGa +  Ug G— — &g Ga 
dt
dG —
Gut ammonia — —— = kgGa — ^gG m  +  ngG u — £glG m  +  k iIp — $g G— dt
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Figure 4.1. A schematic representation of the interactions of nitrogen pools in the 
mathematical model. Nitrogen atoms in ingested molecules are transformed, incorporated 
into tissues, and excreted. Nitrogen in the gut (blue) is processed by the liver (yellow) and 
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The nonlinear terms in the model represent the regulation of the size of the plasma amino 
acid pool, the mucosal protein pool, and the intracellular protein pool, and the formation 
of urea from liver amino acids and ammonia. We assume that the size of protein pools 
are well regulated, so that protein pools will tend toward a given level for a wide range of 
nitrogen intake rates. To achieve this effect, we use mass action like terms to describe the 
regulation of tissue protein production, mucosal protein production, and transfer of amino 
acids from the liver to plasma. For example, intracellular protein is produced by plasma 
amino acid at rate Yp /PA(ipmax -  ip ). We use the mass action term nLLMLa to describe 
the formation, within the liver, of urea from ammonia and amino acids.
4.2.3 Model parameterization
We estimated model parameters for a 65 kg human, using known and estimated param­
eters and steady state pool sizes for an intake rate of nitrogen of 10 g/day (Tabs. 4.2 and 
4.3). Using known and assumed parameters and steady state pool sizes for a =  10 g/day, 
we solved the Gp , M p , and ip  steady state equations for yg, YpM , and yp/, respectively. 
Assuming rapid exchange between the plasma amino acid pool and the liver amino acid
Table 4.2. Variables in nitrogen mode
Variable Description Steady state with a =  10 g N/day Unit Reference
G p Gut protein nitrogen 10 g 14n [76]
Ga Gut amino acid 2.0 g 14n [76]
G m Gut ammonia 0.21 g 14n [76]
Mp Mucosal protein 59 g 14n [76]
La Liver amino acid 1.1 g 14n assumed
Lm Liver ammonia 0.98 g 14n assumed
Lu Liver urea 1.1 g 14n assumed
G u Gut urea 0.76 g 14n [76]
Pa Plasma amino acid 15 g 14n [77]
Ip Intracellular body protein 2300 g 14n [76]
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Table 4.3. Parameters in nitrogen model.
Parameter Description Value Unit Reference
a Dietary protein intake rate 0-30 g 14N/day
VMP Shedding rate from mucosal lining to gut 0.17 1/day [76]
5o Gut nitrogen decay rate 0.1 1/day [76]
Pol Absorption rate of amino acids to portal vein 12 1/day [76]
nL Urea production rate 6.5 1 /g/day [78]
5a Rate of amino acid and protein loss in urine 0.65 1/day [79]
5m Rate of ammonia loss in urine and sweat 0.46 1/day [79]
tlo Rate of urea recycling 6.5 1/day [78]
5l Rate of urea loss in urine 6.5 1/day [78]
no Rate of urea hydrolysis 9.3 1/day [78]
Yip Rate of turnover of body protein 0.017 1/day [80]
Ym p Rate of turnover of body protein 0.017 1/day [80]
mpmax Maximum mucosal protein pool size 59.01 g 14n [76]
'Lpmax Maximum body protein pool size 2300.01 g 14n [76]
pamax Maximum plasma amino acid pool size 16 g 14n [76]
5i Rate of shedding of skin and hair 0.00015 1/day [81]
ki Rate of ammonia production by body protein 0.001 1/day assumed
Yo Degradation rate of protein to amino acid 1 1/day calculated
Yp i Intracellular body protein production rate 278 1/ g 14N/day calculated
Ypm Mucosal protein production rate 74 1/ g 14N/day calculated
ioL Rate of ammonia transfer from gut to liver 18 1/day calculated
kl Rate of liver AA conversion to ammonia 3.4 1/day calculated
Ppl Plasma AA to liver AA transfer rate 100 1/day assumed
Plp Liver AA to plasma AA transfer rate 1513 1/ g 14N/day calculated
Ko Rate of microbial ammonia production in gut 1 1/day assumed
Vo Rate of microbial AA production in gut 36 1/day calculated
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pool, we set [3pl  =  100, and solved the Pa steady state equation for [3l p . Similarly, we set 
kg =  1, and solved the Ga steady state equation for ^G. Using these values, we solved the 
Lm steady state equation for kl , and the Gm steady state equation for ( GL.
4.2.4 Steady states
We numerically found the steady states as a function of dietary nitrogen intake a by 
solving the differential equations at time 106 days. Parameters were set to the values in 
Tab. 4.3 and initial conditions were set to the the steady state values for intake rate of 10 
g/day (Fig. 4.2).
4.2.5 Stable isotope model
We developed equations tracking total nitrogen fluxes. The corresponding 15N differ­
ential equations, with the potential for fractionation, or preference of molecules containing 
either 15N or 14N, in each flux term are:
dG*
Gut protein 15N =  ainRina -  alGygGp +  a VMP v m pM p -  a$G 5gG*p
*dG
Gut ornino acid 15N =  aYG YgGP -  a «GL&GLGA -  a KG kgGa +  a „GHc G'm
- cMg 5GGA
dG*
Gut ammonia ‘ 5N ^  kg G'a -  am Gl,  +  o„g -  a fGL
+ a K! KIIp  -  aSG 5GG *m
dM *
Mucosal protein 15N —d  =  a lPM y p m PA (mpmax -  M p) -  a VMP vm p Mp
- a lMP ym p  Mp
dL*
Liver amino acid 15N =  apGLPglG*a -  a VL2 nlLm L*a -  a KL klL*a
+ afiphPp LP*  -  a fiLPPl p LA(P amax -  Pa) -  asA 5a L*a
dL*
Liver ammonia 15N — M  =  a^GL£g lG*m  +  a KL klL*a -  aVL1 nLL*MLa -  oSm 5m L*m
dL*
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Gut urea 15N ~dfU =  (XrLG TlgLU -  anG VgGU -  a$G 5g GU
dP *
Plasma amino acid 15N —tA =  a1MPy m p M p -  a 1PMYp m Pa (mpmax -  M p )
+ aYJPYIPIP -  aYPjYPIPA( ipmax Ip  )
+ afiLP Plp  L*a (p amax-  PA) -  afPLPp LPa
dl*
Intracellular protein 15N =  alPIYp i P* (ipmax -  Ip ) -  alJPy ip I*p  -  a Kj k iI*p
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4.2.6 Stable isotope steady states as 
function of fractionation
In principle, isotopic fractionation may occur with each term. It is likely, however, that 
fractionation is dominated by a small number of processes. Since urine has a lower isotope 
ratio than diet, it is thought that the process leading to isotopic discrimination is urea 
formation [75].
We set all fractionation factors a  in the 15N differential equations to 1, except the 
fractionation factors associated with urea formation, aVL1 and aVL2, which we set equal to 
each other at a value now referred to as a. We numerically found the 15N steady states for 
a  =  1, 0.996, 0.992, and 0.988 as a function of dietary nitrogen intake a with the isotope 
ratio of diet Rin =  0.003676 (Fig. 4.3).
Stable isotope abundances are reported in 5 notation as parts per thousands (0/oo), where
5 =  (R s -  0 * 1000 0/oo
and Ra and Rs are the molar ratios of the rare to abundant isotope in the sample and the 
standard, respectively. For nitrogen isotopes, the standard is air with a nitrogen isotope 
ratio of RS =  0.003676.
4.2.7 Turnover from change in diet isotope composition
To assess how changes in the isotope ratio of diet propagate to internal pools, we varied 
Rin with time and numerically solved the differential equations (Figs. 4.4 and 4.5). We 
simulated a diet switch by setting Rin to be a step function equal to 0.003676, corresponding 
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Figure 4.3. Nitrogen stable isotope ratios of the 10 pools at steady state as a function of 
dietary nitrogen intake, a, and urea formation fractionation factor, a.
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Figure 4.4. Stable nitrogen isotope ratios of the 10 pools and diet as a function of time 





Figure 4.5. Stable nitrogen isotope ratio of intracellular protein as a function of time for 
a  =  0.990 and a =  3.6, 7.5, 15, and 30. The &15N of diet switches from 0 0/oo to 5 0/oo at 
day 100.
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515Ndiet =  5 0/oo. The total nitrogen dietary intake, a, was fixed at 3.6, 7.5, 10, 15, or 30 
g/day.
4.3 Results
In our model, a minimum dietary nitrogen intake is necessary to maintain plasma amino 
acid and intracellular protein levels (Fig. 4.2). Consistent with Steffee et al. [82], the 
steady state levels of plasma amino acids, intracellular protein, and mucosal protein are 
well regulated, and remain approximately constant with dietary nitrogen intake level, a, 
provided a is greater than about 2.2 g/day. There is almost no urea production for a <  2.2 
g/day, and for a >  2.2 g/day urea production increases linearly with a. The steady state 
levels of gut protein, gut amino acid, liver urea, gut urea, and liver ammonia all also increase 
linearly with a for a >  2.2 g/day.
We extended our nitrogen budget model to account for stable isotope fractionation in 
urea formation. With isotope fractionation occuring only at urea formation, our model 
predicts that urea is isotopically depleted relative to diet that body protein is isotopically 
enriched relative to diet at steady state (Fig. 4.3). The degree of enrichment or depletion 
of the pools depends on both the fractionation factor associated with urea formation, a, as 
well as the dietary protein intake rate, a. For a <  2.2 g/day, almost no urea is produced 
and the 515N of body protein is close to that of diet. As a increases, the 515N of the body 
protein pool increases. The 515N of body protein does not increase linearly, but rather it is 
close to zero for a <  2.2 g/day, and then increases very rapidly, before saturating for large 
a. The 515N of body pools depends on the fractionation factor a. While the characteristic 
shape of the steady state body pool 515N curves as a function of a remain the same, the 
degree of enrichment is determined by the fractionation factor a.
We assessed the turnover rate of the 515N of the body pools, with constant a, and the 
515N of diet switching from 0 to 5 0/00 (Figs. 4.4 and 4.5). Different pools have different 
turnover rates following a change in the isotope ratio of the diet. The gut protein pool turns 
over most rapidly following diet switch, while the intracellular body protein pool turns over 
most slowly. The rate of turnover following a diet switch depends on the dietary nitrogen 
input rate a. The rate of turnover is slowest for low a and increases with a.
4.4 Discussion
We have developed a dynamical model of animal nitrogen metabolism. Our model tracks 
the fate of nitrogen as it is ingested as protein, incorporated into tissues, and excreted.
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The model incorporates known cycling of nitrogen involved with nitrogen urea salvage and 
mucosal lining shedding of protein into the gut, as well as the tight regulation of the size of 
the body protein and plasma amino acid pools.
We also developed a corresponding system of equations that describe the metabolism of 
15N. Fractionation of nitrogen in urea formation is sufficient to explain the 2-6 %o discrim­
ination from diet to tissue. In the model, the mechanism of the tissue-diet discrimination 
is the preferential formation of urea from liver ammonia and amino acids with 14N. The 
dynamics of turnover of the intracellular protein pool are largely determined by the intake 
rate of nitrogen, and the gut protein and amino acid pools have one component with very 
fast turnover and a slow component due to the proteins of endogenous origin.
Schoeller [75] developed a simple conceptual steady state model of nitrogen balance to 
explain consumer diet-tissue nitrogen fractionation. In his framework, isotopes can leave 
the body either through a fractionated route, corresponding to urine, or an unfractionated 
route, corresponding to feces. He argues that nitrogen isotopes in consumer tissue are 
isotopically heavy compared to diet because of fractionation in nitrogen excretion, though 
he does not attempt to explain the large variation in nitrogen isotope consumer tissue-diet 
discrimination. Martinez del Rio et al. [83] developed a similar single pool mathematicaal 
model of nitrogen balance. They argue that the fraction of nitrogen lost through the 
fractionated route should increase with nitrogen intake, explaining the relationship between 
nitrogen intake rate and tissue-diet nitrogen discrimination. The relationship between the 
fraction of nitrogen lost as urea and nitrogen intake is likely complex, and a functional 
relationship is not easily derived.
Fractionation in our model also occurs because of preferential excretion of 15N depleted 
urea, but our model builds upon these models in multiple ways. Our model accounts for the 
known physiology of nitrogen cycling in an animal, including recycling of 15N depleted urea 
and shedding of mucosal proteins, regulation of the size of the protein pool, and regulation of 
urea production. This allows us to estimate the relationship between nitrogen intake rate 
and tissue-diet nitrogen discrimination directly, based on known physiology. Since urea 
formation is regulated, the fraction of nitrogen lost as urea increases with nitrogen intake, 
though the relationship is complex. In our model fractionation occurs in urea formation, 
rather than urea excretion, allowing fractionated urea to recycle through pools in the body. 
Therefore, the relationship between fraction of nitrogen lost as urea and 515N of tissue is 
damped and more complex in our model than in Martinez del Rio et al.
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Balter et al. [71] developed a mass balance model of nitrogen fluxes in an animal. While 
their model accounts for the major cycling of nitrogen in an animal, such as gut urea 
recycling, they did not develop dynamic equations that describe how an animal adapts 
to changes in nitrogen intake rate. Our model also includes the broad scale dynamics of 
nitrogen cycling in an animal, and builds on this model by including dynamic equations 
that account for the regulation of urea formation and the size of body protein pools.
While the general structure of our model is based on physiology, undoubtedly some 
parameters require further refinement. It is thought that a 65 kg human requires a minimum 
intake of about 6.8 g N/day to maintain protein needs [84]. Our model also has a threshold 
such that below a certain intake level intracellular protein levels are not maintained, but 
at an intake of about 2.2 g N/day. However, the intake estimate of 6.8 g N/day may be 
an overestimate since it is likely that some leeway is required when recommending a safe 
minimum intake value. Also, it seems unlikely that the minimum intake value to maintain 
protein needs is only 30 % lower than the average daily intake of 10 g N/day.
Actual turnover rates of individual tissues may vary from those predicted by our model. 
It is known that different tissues, proteins, and amino acids vary in turnover rate and the 
isotopic composition tissues with different turnover rates may provide information regarding 
the timing of of diet history [54]. Our model indicates that turnover may be complicated 
by the structure of nitrogen cycling in an animal. Individual pools do not receive diet 
directly, but rather interact through the free amino acid pool, complicating isotopic turnover 
following a diet switch. The turnover rates of the pools in our model are strongly influenced 
by the rate of dietary nitrogen intake. Lower dietary nitrogen intake leads to greater 
recycling and reuse of amino acids by tissue protein through the free amino acid pool.
Consistent with our model, Sponheimer et al. [85] found greater hair-diet nitrogen 
discrimination in high protein diets in a controlled diet study of two horses. They also 
found that hair turned over quickly following an isotopic diet change, with equilibration 
occuring in less than 24 weeks. Similarly, Huelsemann et al. [86] found rapid turnover of 
nitrogen isotopes in human hair following a diet switch, but speculate the presence of a 
compartment with very slow exchange rate. If individual pools interact through the free 
amino acid pool as described in our model, we predict that tissues with slow turnover rates 
influence the turnover of other tissues such as hair, and experiments with a longer time 
scale are needed to determine if a tissue has truly fully equilibrated. Alternatively, if amino 
acids from diet are routed directly to hair rather than interacting through the free amino
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acid pool, turnover may in fact be as rapid as suggested.
Our mathematical model provides a conceptual framework to better understand con­
sumer tissue-diet nitrogen discrimination. Our model connects urea production to dietary 
nitrogen intake by accounting for basic nitrogen dynamics in an animal. Many other factors 
that are not included in the model may also affect nitrogen tissue-diet isotope discrimination. 
The relationship between protein metabolism and total energy intake and expenditure is 
complex and may affect the nitrogen budget of an animal [65, 66, 67, 70]. If energy intake is 
insufficient to meet energy demands, body proteins may be metabolized for energy. Protein 
quality may also be related to tissue-diet discrimination [58, 59]. If a diet is deficient in one 
or more amino acids, the biologically usable protein intake may actually be lower than the 
actual protein intake. Certain amino acids are highly fractionated while others are not [68], 
which may mean that fractionation also occurs in transamination and deamination processes 
unrelated to urea formation, or that certain amino acids are selectively degraded to urea. 
Amino acids with isotopic ratios different than bulk may be selected for the formation of 
certain tissues. Metabolic routing may occur, such that certain proteins or amino acids are 
preferentially routed to specific tissues or metabolic fates [54, 64]. Our model also assumed 
steady state physiological conditions in an adult. Physiological conditions that affect the 
nitrogen budget of an animal such as pregnancy, growth, wound healing, starvation, and 
the mounting of an immune response may affect nitrogen dynamics. Each of these factors 
represents a potential extension of the model. Nitrogen cycling in an animal is a complex 
process with many feedbacks and contributing cofactors. Our model begins to untangle the 
relationship between nitrogen cycling in an animal, diet, and stable isotope composition of 
tissues.
CHAPTER 5
DECONVOLUTION OF ISOTOPE 
SIGNALS FROM BUNDLES OF 
MULTIPLE HAIRS 
5.1 Introduction
Organic and inorganic substances in mammals are incorporated into hair, remaining 
inert for relatively long periods of time [87]. Human forensic applications have long been 
recognized, as hair records the concentration of drugs, metabolites, toxins, and poisons 
at the time of formation [88, 89, 90, 91]. More recently, ecologists and anthropologists 
have used stable isotopes in hair to infer information about an animal’s diet, migration, 
nutritional status, and environment [61, 92, 54, 93, 94, 95]. While the growth of hair is 
approximately linear, allowing the measurement of long-term chronology through segmental 
sampling, individual hairs typically have too low linear density to allow high-resolution 
sampling of a single hair. Sample sizes vary, but segments for drug testing are typically 
between 10 and 30 mm [88] and generally require 1-300 mg of hair [96]. Stable isotope ratios 
of hydrogen, carbon, nitrogen, oxygen, and sulfur require ca. 200, 50, 300, 200, and 1500 ^g, 
respectively. To achieve these masses for animals with hair of relatively low linear density, 
such as humans, multiple hair strands are typically aligned at the root and combined into 
a single bundle for analysis [88, 97]. The challenge is to mathematically extract the true 
chemical signal recorded in hair given variations in growth rate and stasis, because these 
processes will tend to blur, or average, the temporal information recorded in hair.
Two distinct processes can cause misalignment between individual hair strands in a 
bundle: variation in growth phase [98] and variation in growth rate [97]. Each hair follicle 
cycles through three distinct phases of growth [99, 100]. In humans, approximately ninety 
percent of hairs are typically in the anagen, or growth, phase, which lasts for 48-72 months. 
The anagen phase is followed by a brief catagen phase, during which the follicle stops 
producing hair. The hair then enters the telogen, or resting, phase during which the follicle 
and hair remain dormant for 2-6 months, until the hair is shed. Variation of growth rate
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between individual hairs in the growth phase can also blur the measured signal of a hair 
bundle. The intraindividual coefficient of variation of hair growth in humans is about 0.1 
[101, 102], and similar variation has been observed in horses [103] and elephants [104]. 
Because individual hair strands vary in growth, signal details present in a single hair may 
not be captured in hair bundle measurements due to averaging misaligned hair strands in 
a bundle.
Previous studies assume that the measured bundle signal is equivalent to the signal of a 
single hair in the growth phase with average growth rate. Given known physiology of hair 
growth, we assume that the phase of growth and growth rates of individual hairs will vary 
within a bundle. We have developed a mathematical model of hair growth that describes the 
relationship between the signal of a bundle of hairs and the primary body signal (e.g., the 
isotopic pool in the body at equilibrium with hair). The model is based on an estimation of 
uncertainty in time since formation, or age, of the hair at a given length from the root. We 
used the model to develop an inverse method to estimate the primary body signal from the 
measured signal of a hair bundle. Our inverse method was applied to a previously described 
stable oxygen isotope chronology from a hair bundle of a murder victim [105] and provides 
a refined interpretation of the original data.
5.2 Methods
5.2.1 Model formulation
5.2.1.1 Mapping single hair signal to hair bundle 
measurements
Let 0(t) be the time-dependent primary body signal (e.g., drug, metabolite, isotope, 
etc.) to the hair. The function 0(t) refers to the input signal to the hair (e.g., the isotopic 
pool in the body at equilibrium with hair), not the input signal to the body (e.g., drinking 
water, drug dosage history, etc.), and is assumed to be equivalent to the signal of a single 
hair in the growth phase with the average growth rate. The expected bundle signal as a 
function of length is
i>(l) =  J  A(l, t )0 ( t )dr, (5.1)
where A(l, a) is the probability density function of time since formation, or age, of a hair at 
length l from the root given that the total length of the hair is at least l and the hair has 
not yet been shed. The kernel A quantifies the length-dependent uncertainty in age.
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5.2.1.2 Derivation of A( l , a)
Let A(1, a) be the probability density function for the random variable time since forma­
tion, or age, A, of hair at length l from the root, given that the hair has not been shed and
the total length of the hair is at least l. Let A(1, a) be the cumulative distribution function
d
of A, so that A(1, a) =  —  A(1,a). We assume that hair grows at constant random rate R
da
for random time S , and then rests for random time T . We will find the distribution of A in 
terms of the distributions of R, S, and T  in Tab. 5.1.
Let L be the random variable describing the total length of the hair. A hair strand is 
shed at random time S +  T . Using the law of total probability, we condition on the phase 
of growth of the hair.
A(1, a) =  Pr (A <  a|L >  l and A <  S +  T )
=  Pr(A <  a|L >  l and A <  S)Pr(A  <  S|L >  l and A <  S +  T )+
Pr(A <  a|L >  l and S <  A <  S +  T )Pr(S  <  A <  S +  T|L >  l and A <  S +  T)
Let g(l) =  Pr(A <  S|L >  l and A <  S +  T ). We again use the law of total probability 
to rewrite A(1,a), this time conditioning upon the amount of time that a hair has been 
resting, V , given that it is in the resting phase.
A(1, a) =  g(1)Pr(A <  a|L >  l and A <  S )
+  (1 — g(l)) f  Pr(A <  a|L >  l and S <  A <  S +  T  and V =  t )
Jt=0
* Pr(V  =  t |S <  A <  S +  T)dT 
We will find each of these distributions in terms of the distributions in Tab. 5.1.
Table 5.1. General distributions used in hair bundle modeling
Distribution Description
h probability distribution function for the growth rate of hair, R
H cumulative distribution function for the growth rate of hair, R
probability distribution function for the time spent in growth phase, S
Fs cumulative distribution function for the time spent in growth phase, S
f T probability distribution function for the time spent in resting phase, T
Ft cumulative distribution function for the time spent in resting phase, T
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Pr(A <  a\L >  l and A <  S )
p r o
=  Pr(A <  a\L >  l and A <  S)Pr(R  =  r)dr 
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Similarly,
Pr(A <  a\L >  l and A <  S +  T  and V  =  t )
r
=  Pr(A(l) <  a\L >  l and A <  S +  T  and V  =  t )Pr(R  =  r)dr 
Jo
=  J  Pr ^ -  +  t <  a\L >  l and A <  S +  T  and V  =  t J^ h(r)dr
=  h(r)dr
Jl/(a-r)
=  1 -  H t b )
To find Pr(V  =  t \S <  A <  S + T ), we find the cumulative distribution function, and then 
differentiate. Because the stage of hair growth is well mixed between hairs, the amount of 
time a hair has been resting given that it is in the resting phase, V , is uniformly distributed 
from 0 to T .
Pr(V  <  t \S <  A <  S +  T) =  Pr(V  <  t \S <  A <  S +  T  and T  =  t)Pr(T =  t)dt
Jo
=  / Pr(V  <  t \S <  A <  S +  T  and T  =  t ) fT(t)dt 
Jo J rr t-ro t
=  fT (t)dt +  J  -jfT  (t)dt 
=  Ft  ( t  ) +  t  I  (t)_ -dt 
Jr t
So that
f  CPr(V =  t \S <  A <  S +  T) =  J fT (t)- dt.
t
Again, because the stage of hair growth is well mixed between hairs,
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g(l) =  Pr(A <  S |L >  l and A <  S +  T )
t^o r to r torTO TO TO
/  h(r) / Pr(A <  s|L >  l,A  <  s +  t ,R  =  r ,S  =  s ,T  =  t ) fS(s ) fT(t)dsdtdr
J 0 J 0 J 0
rTO rTO rTO
/  h(r) / Pr(A <  s|l/r <  A <  s +  t, R =  r,S  =  s ,T  =  t ) f S(s ) fT(t)dsdtdr 
J 0 J 0 J00 J0 J0 /•TO /• TO /• s+t s — l / r
h(r) ---- T r f  (s ) fT (t)dsdtdr
10 J0 Jl/r s +  t — l/r
/•TO /• TO /•v „ — l/r
h(r) ------r r  fS (s)fT  (v — s)dsdvdr
'0 ./l/r ./l/r v — l/r
Putting these distributions together we have
where
K(l ,a) =  g (l) ^  — + (1 — g (l)) f o — H  ( — 7 ) )  K(r)dr
/• to /• to /•v s — l/r
g(l) =  / h(r) ------—  fS (s)fT  (v — s)dsdvdr
0 l/r l/r v -  l/r
and
J
K(a) =  /
a
Differentiating with respect to a, we find:
A(l’ a) = g (l)02h ( 0 )  +  ( 1 —g(l)) i  c r h r K(T)h( ; r b ) dT
5.2.1.3 Averaging due to sample interval
Signal attenuation also occurs by combining material over the sample length to obtain 
the mass of material required for analysis. In the case of sampling a single hair that is in the 
growth phase with fixed growth rate r , the expected measured signal, f (l), is the average of 
the time-dependent primary body signal, ^(t), converted to length, over the sample length 
v :
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r r l/r+v/(2r) 
f  (l) =  - /  0 (t ) dT. 
v Jl/r-v/(2r)
/{■l/r+
The center of the samples are at lengths l =  (2i -  1)v/2 where i is a positive integer. 
Sampling a bundle containing a large number of hairs allows for small sample length, so the 
measured signal of a bundle of hairs approaches ^ (l).
5 .2 .2  In verse  m e th o d
To estimate the time-dependent input signal 0(t) from measurements of ^ (l), we dis­
cretized equation 5.1 into the matrix vector equation K f  =  d, where f  is a discretization of 
0(t), d is a vector containing a smoothing of the measured values of ^ (l), and K  is an mxn 
matrix. The smoothing was performed using a cubic smoothing spline with the trace of the 
smoother matrix chosen by generalized cross-validation, and the dimension n was chosen to 
be large enough to obtain an accurate quadrature approximation of A.
As in the estimation of a primary input signal from a measured stable isotope tooth 
enamel signal described by Passey et al. [106], we used Tikhonov regularization to invert 
K , yielding the estimation
fest =  fguess +  K T[K K T +  £2I]-1 [d -  K f guess],
where I  is an identity matrix, f guess is an a priori reference vector, and e is a scalar 
regularization parameter. The reference vector f guess was chosen to be a vector containing 
the mean value of the measurements d.
The damping factor e was chosen using generalized cross-validation. The chosen e 
minimizes the GCV functional
G C V  (e) = 1 2
—trace(I -  A e) 
n
where re =  Kfest -  d and Ae =  K (K TK  +  e2I ) - 1K T [107].
5.3 Results
Using the distributions in Tab. 5.2, the model depends on two parameters: 7  is the 
fraction of hairs in the resting phase (anagen and telogen), and a  is the coefficient of 
variation of hair growth rate. The integral transform kernel, A(l,a), is the probability
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density function of time since formation, or age, of hair at a given length from the root and 
describes the amount of signal attenuation in the hair bundle signal. The kernel A(l, a), 
with y =  0.1 and a  =  0.1, is shown in Fig. 5.1. We varied 7  and a  to assess how 
these parameters affect A(l,a) (Fig. 5.2). A high fraction of hairs in the resting phase, 7 , 
results in high variance in age of hair at all lengths and a mean age that is higher than the 
length divided by the mean growth rate. A high coefficient of variation of hair growth rate, 
a , results in increasing variance of age with length. The distribution of age dictates the 
uncertainty in time when sampling a single hair and also the expected amount of averaging 
from sampling a bundle of multiple hairs.
We compared the expected value of the signal from sampling a bundle of hairs that 
contains hairs with varying growth rates and phases, with a  =  0.1 and 7  =  0 .1, to sampling 
a single hair that has a growth rate of 1 cm/month and sample length v =  1.5 cm (Fig. 5.3). 
The primary body signal is the stable nitrogen isotope record of an elephant tail hair from 
an individual that migrated between two isotopically distinct zones, extended periodically 
to create a longer signal. The primary body signal refers to the signal of the body pool at 
equilibrium with hair and is the signal of a single hair in the growth phase with average 
growth rate. Elephants have thick hairs with high linear density, allowing for high-resolution 
sampling of a single hair. Signal attenuation occurs when sampling a single hair because 
of combining material over the sample length. Combining multiple hairs into a bundle for 
sampling attenuates the primary body signal because of varying growth phases and growth 
rates of hairs in the bundle. Signal details of sufficiently short duration are highly damped 
and are not captured in the bundle signal because of averaging. When sampling a single 
hair, events of duration shorter than the sample length may not be recorded. Additionally, 
when sampling a single hair there is considerable uncertainty in assigning time to length 
since the exact growth rate and phase of growth of the sampled hair is not usually known.
To test the ability of the inverse method to accurately reconstruct a primary body 
signal from measurements, we used the hair bundle model, with a  =  0.1 and 7  =  0 .1, to 
create a synthetic measured bundle signal from an assumed primary body signal. We then 
used the inverse method to estimate the primary body signal from the synthetic bundle 
signal (Fig. 5.4). The primary body signal is from a previously described carbon stable 
isotope record of elephant tail hair in Samburu National Reserve, and represents a typical 
ecologically relevant body signal [93]. The estimated primary body signal is more similar to 
the primary body signal (correlation coefficient R2 =  0.81) than the measured hair bundle
Table 5.2. Parameters and specific distributions used in hair bundle modeling.
Parameter Description Value
Y fraction of hairs in resting phase 0.05, 0.1, 0.3
a coefficient of variation of hair growth rate 0.05, 0.1, 0.25
P average hair growth rate 1 cm/month [101, 97]
V average time from beginning of growth phase to hair shedding 66 months [98]
Distribution Description Value
h hair growth rate probability density function N (P , (P a)2)
time in growth phase probability density function N (v(1  — Y^ (0-1v(1 — Y))2)
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Figure 5.1. The kernel X(l, a) at lengths 2.5 cm, 5 cm, 10 cm, and 20 cm, A-D, respectively, 






























Figure 5.2. Mean, A, and standard deviation, B, of time since formation, or age, of hair 
at a given length from the root for various values of fraction of hairs in the resting phase, 
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Figure 5.3. Expected length-dependent single hair signal and hair bundle signal derived 
from our mathematical model using an assumed time-dependent primary body signal. Time 
indicates months prior to root formation, length indicates cm from root. The signal of the 

















Figure 5.4. A primary body signal that is attenuated from sampling a bundle of hairs 
can be partially reconstructed from measurements using inverse methods. Time indicates 
months prior to root formation, length indicates cm from root.
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signal is to the primary body signal (correlation coefficient R2 =  0.43). High frequency 
details are lost in the estimated input signal, but the general pattern remains well estimated.
The assumed stable isotope primary input signals in Fig. 5.3 and Fig. 5.4 are from single 
elephant tail hairs sampled at 5 mm intervals. Elephants have thick hairs with high linear 
density, allowing for high-resolution sampling of a single hair. The data in Fig. 5.3 represent 
an individual migrating between two areas with different 515N values for vegetation and thus 
an abrupt change in 515N occurs at each migration event [108]; transitions between areas 
were made in less than 12 hours based on GPS-tracking data. Migration events result in a 
signal approximating a step function. Data from this individual are previously unpublished, 
but the individual had behavior analogous to that described by Cerling et al. [108]. The 
data in Fig. 5.4 are from Cerling et al. [93] and represents gradual diet transitions coinciding 
with two rainy seasons per year. Samples were run on an isotope ratio mass spectrometer 
in continuous-flow mode coupled to an elemental analyzer (EA-CF-IRMS).
5.4 Application of inverse method 
to murder victim data
We applied the inverse method to previously described oxygen stable isotope measure­
ments from the organic component of a hair bundle of an unidentified murder victim, with 
Y =  0.1 and a  =  0.1 (Figs. 5.5 and 5.6) [105, 109]. Oxygen stable isotope measurements 
of the organic component of hair can be used to determine time-dependent geographic 
region-of-origin because oxygen isotopes in drinking water vary with location [110] and are 
incorporated into hair [111, 112].
The confidence interval for the estimated primary body signal was obtained by inverting 
data with noise added to each measurement. We created 1000 replicates of measurements by 
adding normally distributed noise with mean zero and standard deviation of 0.15 % 0  to each 
measurement. For each set of measurements with added noise, we selected a regularization 
parameter using generalized cross validation, and performed the inversion using Tikhonov 
regularization to estimate the primary body signal. We excluded 48 estimates of the primary 
body signal because their isotope values lay outside the biologically feasible range of 7 to 
16 % 0. The shaded region corresponds 518O within two standard deviations of the mean 
estimated primary body signal.
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Figure 5.5. Estimated primary body signal and equilibrium signal from hair 518O 
measurements of a previously described hair bundle of a murder victim.
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Figure 5.6. Tap water maps for geographic regions predicted by the estimated equilibrium 
signal.
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5.4.1 Estimating equilibrium signal from 
estimated primary body signal
The model inversion yields an estimate of the primary body pool at equilibrium with the 
hair, not the input signal to the body. The body equilibrium signal refers to the primary 
body signal if it were in instantaneous equilibrium with the input. The body equilibrium 
signal can be reconstructed using a previously described method based on multiple pools 
with first order kinetics contributing to the primary body pool that is at equilibrium 
with hair [113, 114]. Briefly, the isotope composition of the j th pool contributing to hair 
formation at time t is
Sjj =  5j-1 e -XjAt +  5eq(1 -  e -XjAt)
where dj-1 is the isotope composition of the j th pool at time t -  1, At is the difference in 
time between t -  1 and t, Aj is the rate constant of the j th pool, and 5eq is the isotope 
composition of the pool if it were at instantaneous equilibrium with the environment. For a 
p pool system, 5eq can be calculated incrementally from the stable isotope signal of a single 
hair, , as
,t  =  SiH -  E IU  fi^i-1 e-XiAt
eq £ P U  fi (1 -  e -XiAt) 
where f i is the fractional contribution of of pool i to the pool at equilibrium with hair. For 
application to the murder victim, we used a single pool with half-life of 7 days.
5.4.2 Region-of-origin maps
Region-of-origin maps were created in two steps. For each region, we used the semi- 
mechanistic model by Ehleringer et al. [112] to predict drinking water 518O values required 
to produce the hair isotope ratio, with an added 0.5 0/oo to either side of the hair value. 
Once the maximum and minimum 518O values of drinking water were predicted for each 
isotopic region, we used the 518O tap water isoscape produced by Bowen et al. [115] for 
the contiguous United States to identify regions with isotope values matching our predicted 
range. Regions with matching isotope values were highlighted in color using ArcGIS 9.3.1(g).
The data were originally interpreted as movement between three isotopically distinct 
geographic regions, Regions 1,2, and 3, corresponding to measured 518O values of approxi­
mately 9.9 0/oo, 8.4 0/oo, and 9.2 0/oo, respectivly. The transitions from Region 1 to Region 2 
and from Region 2 to Region 1 at about 20 cm and 15 cm, respectively, occur over multiple
81
cm (or equivalently multiple months) of growth, slow movement between geographic regions. 
The transitions from Region 1 to Region 3 and from Region 3 to Region 1 at about 9 cm and 
5 cm, respectively, occur over a short length interval, rapid movement between geographic 
regions. Region 1 is consistent with the location where the victim was found, Salt Lake 
City, UT.
The inverse method was applied to the measured hair £18O to estimate the primary body 
signal. In addition to averaging due to hair bundling, turnover of the primary body pool 
must also be accounted for to determine geographic search regions. We used a previously 
described method [113, 114] to estimate the isotopic composition of the primary body pool if 
it were at instantaneous equilibrium with the environment from the estimated primary body 
signal. To estimate the equilibrium signal, we assumed a single pool with turnover half-life 
of 7 days, which is consistent with observations of hair oxygen stable isotopes in humans 
(calculated from [111, 112]). In this case, the estimated equilibrium signal is very similar 
to the estimated primary body signal (correlation coefficient R2 =  0.89) because of rapid 
turnover of the primary body pool relative to changes in the input signal. Estimated tap 
water maps were produced using a previously described relationship between hair organic 
£18O and drinking water £18O [112] and a relationship between tap water and geography
[115].
The estimated equilibrium signal differs from the measured hair bundle in several impor­
tant ways (Figs. 5.5, 5.6, 5.7, and 5.8). Transitions between isotopically distinct regions are 
more rapid, with more time spent in each region. Region 2* and Region 3* have lower 518O 
than Region 2 and Region 3, respectively, and correspond to different geographic regions 
(Fig. 5.7). Regions 2* and 3* have considerable overlap (Fig. 5.8), suggesting that they 
may correspond to the same geographic location. Region 1 is isotopically similar in both 
the measurements and the estimated equilibrium signal, and the 518O is consistent with 
the location where the victim was found. The estimated equilibrium signal has a new short 
duration region, Region 4, with £18O of about 10.9 %0 that does not appear in the measured 
hair bundle signal. Plotted maps were restricted to the western United States. Region 4 
also contains a small region in the northeast United States as well as parts of Canada.
5.5 Discussion
Multiple hairs that may be in different growth phases and have different growth rates are 
typically combined into a single bundle of hairs for segmental analysis. We have developed a
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Figure 5.7. Comparison of Region 2 with Region 2* and Region 3 with Region 3*.
F igure 5.8. Comparison of Region 2* with Region 3*.
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mathematical model that describes the signal averaging caused by bundling hairs for analysis 
as well as an inverse method to estimate the primary body signal from measurements of 
a hair bundle. If the growth rates of hairs within a bundle vary substantially or a high 
proportion of hairs are in the resting phase of hair growth, the measured hair bundle signal 
is highly averaged relative to the primary body signal, which may lead to misinterpretation 
of the signal.
Our model is based on uncertainty in time since formation, or age, of hair a given length 
from the root. Assigning times to length when sampling a single hair strand also relies on 
an estimation of length-dependent age variation. High variation in growth rates or a high 
proportion of hairs in the resting phase of hair growth leads to high uncertainty in assigning 
time to measurements along the length of a single hair strand.
The determination of whether to bundle hairs or sample a single hair depends on the 
research question. If precise timing of an event is critical or high-resolution sampling is 
desired to capture events in the recent past, multiple hairs should be combined into a 
bundle to decrease sample length and reduce uncertainty in the time corresponding to 
measurements. If multiple hairs are to be combined, it is preferred to combine many hairs 
rather than few, as the uncertainty in the bundle signal decreases with the number of hairs. 
If the amplitude of a long duration event is more important or an individual hair strand 
has high enough linear density to allow for a high-resolution sample interval, sampling 
a single hair strand may result in less signal averaging than sampling a bundle of hairs. 
When sampling a single hair, however, there may be high uncertainty in assigning time to 
measurements.
The inverse method we developed allows for the estimation of the primary body signal 
from a measured hair bundle signal. The method is especially useful in situations where the 
primary body signal is averaged, but characteristics of the signal remain. If the averaging 
is significant enough, however, noise may dominate, preventing meaningful reconstruction 
of the primary body signal.
It may be possible to minimize signal averaging from bundling multiple hairs by ensuring 
hairs are in the growth phase. Van Scott et al. have described a technique to examine a 
hair’s follicle to determine its phase of growth [116], though this is only possible if a hair’s 
root can be observed (i.e., hair was plucked rather than cut). Excluding hairs in the resting 
phase from a bundle has been shown to reduce the growth cycle error in hair stable isotope 
analysis [117]. This can be incorporated into our model by reducing 7 , the fraction of hairs
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in the resting phase, which results in less signal averaging. If the hair has never been cut, 
selecting hairs for analysis with small total length also increases the likelihood of hair being 
in the growth phase. Since each hair grows for a period of time before shedding, hairs with 
small total length are more likely to be in the growth phase. However, the bundled signal 
will still be attenuated due to variation in growth rate of individual hairs.
We applied our inverse method to a previously described [105, 109] oxygen stable isotope 
chronology from the organic component of the hair of a murder victim. The signal obtained 
from the inverse method is an estimate of the 518O of the primary body pool that is in 
equilibrium with the hair, rather than the time-dependent isotopic composition of drinking 
water. Applying a model of turnover of the primary body pool 518O to the estimated 
primary body signal provides an estimate of the equilibrium signal. This further sharpens 
the transitions between regions, though the effect is small due to the relatively rapid turnover 
of oxygen isotopes in the primary body pool at equilibrium with hair. In cases where 
turnover of the body pool at equilibrium with hair is slow (e.g., carbon [118] and nitrogen 
isotopes [85]), the signal attenuation caused by turnover of the body pool may be larger 
than that caused by bundling multiple hairs. The search maps determined by the estimated 
equilibrium signal differ from previously published interpretations in several important ways. 
Transitions between isotopically distinct regions are more rapid, and the 518O of the regions 
are different. An additional region of short duration is present in the estimated equilibrium, 
that may have been have averaged by measuring a bundle of multiple hairs.
Similar methods may also be used to estimate uncertainty in time since formation, when 
time cannot be constrained using other methods, in other length-dependent measurements 
of “ecological tape recorders,” such as measurements of nails, horn, or tropical trees lacking 
growth rings. Additionally, similar probability density functions may be useful for esti­
mating the uncertainty in age of an animal or plant from size or length. The details of 
these methods will depend on growth characteristics. Other biological systems, such as 
cell-cycle dependent processes, also rely on inverse methods to estimate individual signal 
from population-level measurements [119, 120, 121, 122]. In these models, variation in 
cell-cycle phase of individual cells can result in important differences between population 
measurements and individual cell dynamics.
Hair records the concentration of drugs, toxins, metabolites, and stable isotopes in the 
body as it grows. Segmental analysis of a bundle of hair allows for the construction of 
a high-resolution record of the history of an animal. However, variation in the growth of
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individual hair strands can distort the relation between measurements and the actual history 
of the animal. Our mathematical model provides an estimate of uncertainty in time since 
formation, or age, of a hair strand a given length from the root as well as an inverse method 
to estimate the time-dependent primary body signal (e.g., drug, metabolite, isotope, etc.) 
from segmental analysis of a bundle of hairs, based on measurable growth characteristics of 
individual hair strands.
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